Skip to main content
PLOS Biology logoLink to PLOS Biology
. 2020 Sep 29;18(9):e3000813. doi: 10.1371/journal.pbio.3000813

Short-chain fatty acids bind to apoptosis-associated speck-like protein to activate inflammasome complex to prevent Salmonella infection

Hitoshi Tsugawa 1,‡,*, Yasuaki Kabe 1,2,‡,*, Ayaka Kanai 1, Yuki Sugiura 1, Shigeaki Hida 3, Shun’ichiro Taniguchi 4, Toshio Takahashi 5, Hidenori Matsui 6, Zenta Yasukawa 7, Hiroyuki Itou 8, Keiyo Takubo 9, Hidekazu Suzuki 10, Kenya Honda 11, Hiroshi Handa 12, Makoto Suematsu 1,*
Editor: Matthew K Waldor13
PMCID: PMC7524008  PMID: 32991574

Abstract

Short-chain fatty acids (SCFAs) produced by gastrointestinal microbiota regulate immune responses, but host molecular mechanisms remain unknown. Unbiased screening using SCFA-conjugated affinity nanobeads identified apoptosis-associated speck-like protein (ASC), an adaptor protein of inflammasome complex, as a noncanonical SCFA receptor besides GPRs. SCFAs promoted inflammasome activation in macrophages by binding to its ASC PYRIN domain. Activated inflammasome suppressed survival of Salmonella enterica serovar Typhimurium (S. Typhimurium) in macrophages by pyroptosis and facilitated neutrophil recruitment to promote bacterial elimination and thus inhibit systemic dissemination in the host. Administration of SCFAs or dietary fibers, which are fermented to SCFAs by gut bacteria, significantly prolonged the survival of S. Typhimurium–infected mice through ASC-mediated inflammasome activation. SCFAs penetrated into the inflammatory region of the infected gut mucosa to protect against infection. This study provided evidence that SCFAs suppress Salmonella infection via inflammasome activation, shedding new light on the therapeutic activity of dietary fiber.


This study shows that short-chain fatty acids (SCFAs) bind to the inflammasome adaptor protein, apoptosis-associated speck-like protein (ASC). SCFAs thereby promote inflammasome activation in macrophages and protect against Salmonella infection via bacterial elimination in gut, shedding new light on the therapeutic activity of dietary fiber.

Introduction

The gastrointestinal microbiota consists of nearly 100 trillion bacteria, comprising more than 1,000 species [1]. Gut commensal bacteria, mainly of the phyla Firmicutes and Bacteroidetes, abundantly produce short-chain fatty acids (SCFAs) by fermenting indigestible carbohydrates or dietary fiber [2]. These SCFA-producing bacteria protect against colonization by enteric pathogens, such as Shigella spp., Escherichia coli, and Salmonella spp. [3]. A lack of dietary fiber reportedly promotes epithelial adherence of Citrobacter rodentium, leading to lethal colitis in mice [4]. In addition, partially hydrolyzed guar gum (PHGG), a type of dietary fiber, prevents colonization of Salmonella Enteritidis in young and laying hens [5]. These reports suggest that SCFAs play a protective role against pathogenic infection in the intestinal tract.

SCFAs contain fewer than six carbons, and acetate (C2), propionate (C3), and butyrate (C4) account for 90%–95% of SCFAs in the gut [6]. The G-protein-coupled receptor GPR43 activates the release of glucagon-like peptide 1 from endocrine L cells in the intestinal tract, which leads to improvement of glucose tolerance [7]. SCFAs directly bind to GPR43 to suppress insulin-mediated fat accumulation in adipose tissue [8]. Moreover, SCFAs inhibit histone deacetylase activity [9] and thus regulate the expression of aldehyde dehydrogenases [10], the antimicrobial peptide LL-37 [11], and the transcription factor FOXP3, which promotes regulatory T-cell differentiation [12]. Further, SCFAs reportedly not only promote the production of inflammatory mediators by macrophages but also induce ROS production and phagocytosis by neutrophils [13,14]. If SCFAs strongly induce excessive ROS production by neutrophils, gut commensal bacteria controlling the colonization and/or expansion of pathogens might be eliminated [15]. The detailed effects of SCFAs on the function of immune cells with respect to protection against pathogens remain unknown. In particular, which molecule(s) in immune cells react with SCFAs to regulate innate immunity remains incompletely understood, and authentic receptors for SCFAs must be identified to reveal their protective mechanisms against pathogen infection. This study aimed to identify SCFA receptors that contribute to the regulation of innate immune responses. To this end, we used high-performance affinity nanobeads, which enable direct purification of binding proteins for small-molecule compounds [16,17]. Using SCFA-bound beads, apoptosis-associated speck-like protein containing a caspase recruiting domain (ASC) was identified as an SCFA-binding protein. ASC is a critical component of the inflammasome complex that bridges nucleotide-binding oligomerization domain-like receptor proteins (NLRPs) and caspase-1 [18,19]. ASC contains two functional domains, a PYRIN domain, which is necessary for interaction with the PYRIN domain of NLRPs, and a caspase activation and recruitment domain (CARD), which interacts with caspase-1 [20,21]. The results revealed that SCFA binding to the PYRIN domains of ASC and NLRPs triggered inflammasome complex formation to promote caspase-1 activation, resulting in interleukin (IL)-1β and IL-18 induction and protection against Salmonella enterica serovar Typhimurium (S. Typhimurium) infection.

Results

Identification of ASC as a novel SCFA-binding protein

We used affinity nanobeads to identify SCFA-binding proteins. As direct coupling of mono-carbonates such as propionate or butyrate to beads masked their carboxylic groups, cyclic anhydrides such as succinate anhydride and glutaric anhydride were coupled to amino-modified beads (Fig 1A) to produce SCFA-conjugated beads with SCFAs containing their innate carboxylic groups. Affinity beads conjugated to acrylate, an unsaturated fatty acid, were prepared as a negative control in which malate anhydride was used. Human U937 monoblastic leukemia cell line is known to exhibit the morphology and characteristics of mature macrophages and is able to respond to many exogenous stimuli. To identify authentic SCFA receptors in immune cells in order to evaluate their role in protection against pathogenic infection, we conducted a binding assay using SCFA-conjugated beads and the soluble (cytosolic) fraction of U937 cells. We detected some proteins that bind specifically to propionate and butyrate but not to acrylate (Fig 1B). Peptide sequencing by electrospray ionization (ESI)-mass spectroscopy (MS) identified a protein with an apparent molecular mass of 25 kDa as the inflammasome adaptor protein ASC, after analyzing the protein bands that specifically bound to propionate and butyrate. The specificity of ASC binding to propionate or butyrate was evaluated by a binding assay using recombinant ASC protein. ASC binding to propionate-conjugated beads was abolished by the addition of free propionate or butyrate (Fig 1C) but not by the addition of lactate, which contains a hydroxyl group. These results suggested that a linear saturated carbon backbone is necessary for ASC binding to fatty acids.

Fig 1. SCFAs bind to PYRIN domain–containing proteins.

Fig 1

(A) Schematic representation of the conjugation of propionate, acrylate, and butyrate to amino-modified affinity beads using succinate anhydride, malate anhydride, and glutaric anhydride, respectively. (B) Identification of ASC/PYCARD as a SCFA-binding protein. Propionate (Pro)-, acrylate (Acryl)-, or butyrate (But)-conjugated beads were incubated with U937 cell lysate. Bound proteins were visualized by silver staining and identified by ESI-MS peptide sequencing. (C) Competition assay for binding between ASC and propionate. Recombinant ASC was pretreated with propionate, butyrate, or lactate and then incubated with control (–) or propionate-conjugated beads. Bound protein was visualized by silver staining. (D) Alignment of the a.a. sequences of the PYRIN domains of ASC and NLRP1, 3, 4, and 6 using the Genetyx program. (E) Propionate binds to the Lys-rich domain of ASC/PYCARD. Recombinant ASC (full-length or the deletion mutants) was incubated with control (–) or propionate-conjugated beads, and bound proteins were visualized by silver staining. (F) Propionate-binding assays were performed with PYRIN domain–containing NLRPs (NLRPs 1, 3, 4, and 6) using propionate-conjugated beads. a.a., amino acid; ASC, apoptosis-associated speck-like protein; CARD, caspase activation and recruitment domain; ESI-MS, electrospray ionization–mass spectroscopy; Lys, lysine; NLRP, nucleotide-binding oligomerization domain-like receptor protein; SCFA, short-chain fatty acid.

SCFAs bind to the lysine-rich region of the PYRIN domain

The PYRIN domain is characterized by the presence of a lysine (Lys)-rich basic sequence (-KKFKLK-) that is well conserved among ASC and NLRPs and is required for binding of these proteins (Fig 1D). As SCFAs have a simple structure containing only one carboxylic acid group, we hypothesized that they bind to the basic region of the ASC PYRIN domain. To assess this hypothesis, we conducted binding assays using various deletion mutants of ASC (Fig 1E). Whereas propionate was able to bind full-length ASC and a Δ18 mutant (amino acids [a.a.] 19–195), it did not bind a Δ27 mutant (a.a. 28–195) lacking the Lys-rich sequence (Fig 1E). As NLRPs also contain the Lys-rich sequence (Fig 1D), we further examined the ability of NLRPs to bind propionate. NLRPs 1, 3, 4, and 6 also bound to the propionate-conjugated beads (Fig 1F). These results demonstrated that SCFAs can recognize the Lys-rich sequences of the PYRIN family proteins listed in Fig 1D.

SCFAs enhance inflammasome activation by promoting the binding of ASC to NLRPs

As PYRIN domain–mediated binding of ASC to NLRPs is required for inflammasome activation, we examined the effect of SCFAs on ASC/NLRP binding by a glutathione-S-transferase (GST) pull-down assay. GST-tagged ASC protein was incubated with recombinant NLRP3 in the absence or presence of propionate, butyrate, or lactate at various concentrations (Fig 2A). Both propionate and butyrate, but not lactate, significantly enhanced the binding of NLRP3 to ASC in a dose-dependent manner. A coimmunoprecipitation assay revealed that ASC-NLRP3 interaction was also enhanced in HEK293T cells overexpressing FLAG-ASC and NLRP3 incubated with increasing concentrations of propionate or butyrate, but not in cells incubated with lactate (Fig 2B). Activation of the inflammasome complex leads to the production of mature IL-1β or IL-18 through caspase-1 activation. We examined the effect of SCFAs on IL-1β and IL-18 production in U937 cells treated with lipopolysaccharide (LPS) and ATP, which induce NLRP3-mediated inflammasome activity. The production of IL-1β and IL-18 was significantly increased upon treatment with propionate and butyrate, but not lactate (Fig 2C). IL-1β production induced by treatment with the NLRP3 activators LPS/nigericin and alum adjuvant or the NLRP1 activator anthrax lethal toxin was examined in the presence of SCFAs. Propionate and butyrate, but not lactate, enhanced IL-1β production (S1 Fig). To clarify the structure-activity relationship between SCFAs and inflammasome activation, the effects of various fatty-acid derivatives, including mono-fatty acids, branched carboxylic acids, and di- and tri-carboxylic acids, on induced IL-1β production were analyzed (S2 Fig). LPS/ATP-induced IL-1β production was increased by treatment with mono-carboxylic fatty acids, and the activity was higher in response to fatty acids with shorter carbon chains, such as acetate (C2), propionate (C3), and butyrate (C4), than to those with longer carbon chains, such as valeric acid (C5), caproic acid (C6), enanthic acid (C7), and caprylic acid (C8). In contrast, branched and di- and tri-carboxylic acids did not affect IL-1β production (Fig 2D). These results revealed that mono-carboxylic acids with linear, saturated short chains, but not those with branched carboxylic structures, promote IL-1β production.

Fig 2. SCFAs induce inflammasome activation by enhancing oligomerization of the inflammasome complex.

Fig 2

(A) SCFAs promote the binding between ASC and NLRP3 in vitro. GST or GST-ASC was incubated with fluorescently labeled NLRP3 in the presence or absence of propionate (left), butyrate (middle), or lactate (right). Proteins were visualized by fluorescence imaging (top) or Coomassie Brilliant Blue staining (bottom). (B) Expression vector for FLAG-ASC and/or NLRP3 was transfected into HEK293T cells treated with propionate, butyrate, or lactate. Cell lysates were subjected to coimmunoprecipitation using anti-FLAG resin, and bound proteins were visualized by western blotting using anti-FLAG or anti-NLRP3 antibody. (C) U937 cells were incubated with LPS/ATP and treated with propionate (Pro), butyrate (But), or lactate (Lac). The IL-1β (left) and IL-18 (right) levels in the culture media were measured by ELISA. Data are the mean ± SD of three independent assays. *P < 0.05, **P < 0.01. Data are listed in S1 Data. (D) The effects of SCFA derivatives on IL-1β production were analyzed as shown above. C2, acetate; C3, propionate; C4, butyrate; C5, valerate; C6, caproate; C7, enanthate; C8, caprylate; Lac, lactate; MeP, 2-methylpropanoic acid; Ala, alanine; Mal, maleate; Suc, succinate; Cit, citrate. Data are the mean ± SD of three independent assays. *P < 0.05, **P < 0.01 versus LPS/ATP treatment. Data are listed in S1 Data. ASC, apoptosis-associated speck-like protein; GST, glutathione-S-transferase; IL, interleukin; IP, immunoprecipitation; LPS, lipopolysaccharide; NLRP, nucleotide-binding oligomerization domain-like receptor protein; SCFA, short-chain fatty acid; SD, standard deviation.

SCFAs eliminate S. Typhimurium in macrophages by activating the inflammasome

S. Typhimurium invades and proliferates inside macrophages. We next examined whether SCFAs enhance the S. Typhimurium elimination inside murine bone marrow–derived macrophages (BMDMs) by promoting inflammasome activation. Time-course analyses revealed that upon treatment with acetate, propionate, or butyrate, but not lactate, the bacterial cell number inside BMDMs significantly decreased from 8 hours after infection and the production of IL-1β was also significantly increased compared with nontreated BMDMs, suggesting that enhanced inflammasome activation by SCFAs promote the elimination of S. Typhimurium in BMDMs (S3A and S3B Fig). We next examined whether the antiproliferative effect of SCFAs depends on ASC by using ASC knockout (ASC−/−) BMDMs (S4A Fig). The decrease in the number of bacterial cells at 15 hours after infection detected in wild-type BMDMs treated with SCFAs was not observed in ASC−/− BMDMs (Fig 3A left and middle panel). As SCFAs regulate GPR43 signaling [22], we assessed the antiproliferative actions of SCFAs in GPR43 knockout (GPR43−/−) BMDMs infected with S. Typhimurium. To this end, GPR43−/− mice were generated by clustered regularly interspersed short palindromic repeats (CRISPR)–CRISPR-associated protein 9 (Cas9) gene editing (S4B and S4C Fig). Treatment with acetate, propionate, or butyrate, but not lactate, decreased the number of S. Typhimurium cells in GPR43−/− BMDMs (Fig 3A right panel). Treatment with acetate, propionate, or butyrate facilitated the production of cleaved caspase-1 p20, which is generated upon inflammasome activation, in wild-type and GPR43−/−, but not ASC−/− BMDMs infected with S. Typhimurium (Fig 3B). To determine whether pyroptotic cell death is induced upon activation of caspase-1, the release of lactate dehydrogenase (LDH), an indicator of pyroptosis via caspase-1 activation, from BMDMs infected with S. Typhimurium was measured. LDH release from wild-type and GPR43−/− BMDMs infected with S. Typhimurium was strongly enhanced in the presence of acetate, propionate, or butyrate, but this increase was not observed in ASC−/− BMDMs (Figs 3C and S3C). In addition, IL-1β production in wild-type and GPR43−/− BMDMs infected with S. Typhimurium was robustly increased upon treatment with acetate, propionate, or butyrate (Fig 3D). These results showed that SCFAs accelerate bacterial elimination by enhancing inflammasome activation in S. Typhimurium–infected BMDMs through ASC-dependent mechanisms. As SCFA uptake is mediated by proton-linked monocarboxylate transporter (MCT) [23,24], we assessed the effect of SR13800, a potent MCT inhibitor [25], on the antiproliferative effect of SCFAs in S. Typhimurium–infected BMDMs. SR13800 attenuated the antiproliferative effects of SCFAs at concentrations higher than 20 μM (Fig 3E). In addition, SR13800 suppressed the increase in IL-1β production in S. Typhimurium–infected BMDMs induced by SCFAs, in a dose-dependent manner (Fig 3F).

Fig 3. SCFAs enhance the elimination of S. Typhimurium in macrophages by increasing inflammasome activity.

Fig 3

(A) BMDMs derived from wild-type, ASC−/−, or GPR43−/− mice were infected with S. Typhimurium strain A at multiplicity of infection of 5 for 10 minutes and then incubated in DMEM containing 100 μg/mL gentamycin for 15 hours with or without treatment with 10 mM acetate (Ace), propionate (Pro), butyrate (But), or lactate (Lac). The percentages of surviving S. Typhimurium strain A in comparison with untreated macrophages (ctrl) are shown. Data are the mean ± SD of three independent assays. *P < 0.05, **P < 0.01. Data are listed in S1 Data. (B) BMDMs were prepared as described above, and cell supernatants were collected and precipitated with 10% trichloroacetic acid. The precipitated proteins were subjected to western blotting with an anti-caspase-1 antibody. (C and D) BMDMs were prepared as described above, and cell supernatants were collected and LDH release and IL-1β production in the cell culture media as determined by LDH assay and ELISA, respectively. Data are the mean ± SD of three independent assays. *P < 0.05, **P < 0.01. Data listed in S1 Data. (E and F) BMDMs were treated with the MCT inhibitor SR13800 for 24 hours prior to S. Typhimurium strain A infection, and S. Typhimurium strain A–infected BMDMs were prepared as described above. The cells were lysed, and the bacterial cells within BMDMs were counted. IL-1β levels in the culture media were determined by ELISA. Data are the mean ± SD of three independent assays. *P < 0.05. Data listed in S1 Data. BMDM, bone marrow–derived macrophage; CFU, colony-forming unit; DMEM, Dulbecco’s modified Eagle’s medium; IL, interleukin; LDH, lactate dehydrogenase; MCT, monocarboxylate transporter; ND, not detected (below the detection limit); S. Typhimurium, S. enterica serovar Typhimurium; SCFA, short-chain fatty acid; SD, standard deviation.

Next, we investigated direct effects of SCFAs on the bacteria. Bacterial growth was not inhibited in culture medium supplemented with SCFAs (S5A Fig). As flagellin of S. Typhimurium activates the inflammasome [26,27], we assessed whether exposure to SCFAs would increase flagellin expression in S. Typhimurium. The expression of two flagellin genes (fliC and fliB) of S. Typhimurium was not affected by treatment with 10 mM acetate, 10 mM propionate, 10 mM butyrate, or 10 mM lactate (S5B Fig). The Salmonella pathogenicity island 1 (SPI-1), which is the virulence genes of S. Typhimurium, is also known to induce the activation of the inflammasome [28,29]. Low concentrations of SCFAs in streptomycin-treated mice enhanced colonization in the ileum by increasing SPI-1 expression, whereas SCFAs at a concentration of 30 mM decreased the expression of SPI-1 genes in vitro [30,31]. Our results showed that SCFAs at a concentration of 10 mM enhanced the elimination of S. Typhimurium in BMDMs by promoting inflammasome activation through ASC-dependent mechanisms. Therefore, we examined the effect of SCFAs at a concentration of 10 mM on the expression of SPI-1 genes in S. Typhimurium strain A. The expression of SPI-1 genes (sipD and prgH) did not change by treatment with 10 mM propionate, 10 mM butyrate, or 10 mM lactate (S6A Fig), indicating that the enhanced elimination of S. Typhimurium in BMDMs by 10 mM SCFAs is independent of the down-regulation of SPI-1 genes in vitro. We also evaluated the effect of SCFAs on inflammasome activation in BMDMs using S. Typhimurium SPI-1 knock-down strains. The SPI-1 knock-down strain of S. Typhimurium was constructed by introducing an in-frame deletion of sipB, a transcriptional activator of SPI-1, and we confirmed that the expression of SPI-1 genes (sipD and prgH) was significantly repressed in S. Typhimurium SPI-1 knock-down strains (S6A Fig). When using the SPI-1 knock-down strain of S. Typhimurium, the infection number in BMDMs and LDH release were not changed by ASC knockout, and only a nonsignificant effect by SCFAs was observed in wild-type BMDMs (S6B and S6C Fig). On the other hand, the IL-1β production from wild-type BMDMs, but not ASC−/− BMDMs, infected with S. Typhimurium SPI-1 knock-down strains, was significantly increased by treatment with 10 mM propionate or 10 mM butyrate (S6D Fig). These results suggest that SCFAs can enhance the production of IL-1β through an ASC-dependent mechanism in macrophages infected with SPI-1 knock-down S. Typhimurium, but the pyroptosis associated with the elimination of the S. Typhimurium SPI-1 knock-down strain is independent of ASC.

SCFAs contribute to ASC-dependent host protection against S. Typhimurium infection

ASC/ mice were used to examine the involvement of ASC in host defense against S. Typhimurium. Specific pathogen-free (SPF) ASC−/− mice were cohoused with SPF wild-type mice and then were infected with S. Typhimurium. To confirm that S. Typhimurium strain A is not inherent pathogenicity, we first compared the pathogenicity of S. Typhimurium strain A with that of the S. Typhimurium ATCC14028S strain in mice. There was no difference in the susceptibility of mice against S. Typhimurium strain A and S. Typhimurium ATCC14028S strain (S7A Fig). In addition, in these mice, no difference was also observed in the degree of inflammatory cell infiltration in the cecal mucosa (S7B Fig). Therefore, S. Typhimurium strain A was used for further host protection experiments. SPF ASC−/− mice were significantly more susceptible to S. Typhimurium infection than wild-type SPF mice, suggesting that ASC contributes to host defense against S. Typhimurium infection (Fig 4A). To compare the microbiota in wild-type and ASC−/− mice, the 16S rRNA metagenomes of gut microbiota from wild-type and ASC−/− mice were analyzed. There was no significant difference in the diversity of gut microbiota between wild-type and ASC−/− mice (S8A Fig). Moreover, the results of the principal coordinate analysis (PCoA) plots also showed no difference in the microbiome composition between wild-type and ASC−/− mice (S8B Fig). These results suggest that the increased susceptibility of SPF ASC−/− mice to S. Typhimurium depends directly on ASC, not on a difference in the microflora. Next, to exclude the influence of SCFAs produced by gut commensal microorganisms in SPF mice, antibiotics (ampicillin, metronidazole, neomycin, and vancomycin) were orally administered to SPF mice for 4 weeks prior to S. Typhimurium infection. Under these conditions, there was no difference in susceptibility against S. Typhimurium infection between wild-type and ASC−/− mice, suggesting that the protective effect of ASC depends on the gut microbiota (Fig 4A right panel). Next, the antibiotic-treated mice were given drinking water containing 300 mM SCFAs (propionate or butyrate) or 300 mM lactate for 1 week prior to S. Typhimurium infection (Fig 4B). Treatment with antibiotics significantly reduced the concentrations of propionate and butyrate in the cecal lumen (S9 Fig). It was difficult to determine the exact concentration of the SCFAs of the cecal lumen of the mice given the drinking water containing 300 mM SCFAs because the timing and amount of water intake are different in each mouse, resulting in inconsistent data. Therefore, to measure the concentration of SCFAs in the cecal lumen of the mice immediately after exogenous administration of SCFAs, the mice were forced to drink orally with 100 μL of 300 mM SCFAs before 2 hours, and the SCFA concentrations in the cecal lumen were measured. The exogenous administration of SCFAs restored their concentrations to the levels observed in SPF mice not treated with antibiotics (S9 Fig). The lactate concentration in the cecal lumen was not substantially decreased upon antibiotics administration and was significantly increased upon oral administration of lactate (S9 Fig). Administration of propionate or butyrate, but not lactate, significantly prolonged the survival of S. Typhimurium–infected wild-type mice (Fig 4C). Notably, propionate- and butyrate-treated GPR43−/− mice showed significantly improved resistance to S. Typhimurium infection (S10 Fig), suggesting that the effect of exogenous SCFAs is not mediated by GPR43. In contrast, S. Typhimurium–infected ASC−/− mice did not show any improvement in survival upon treatment with propionate or butyrate (Fig 4D). These findings demonstrated that propionate and butyrate are essential for ASC-dependent host-protective responses. We next examined the bacterial burden in the cecum contents, cecum tissues, mesenteric lymph nodes (MLNs), livers, and spleens of infected mice at 2 days post infection. We observed no significant change in the number of bacterial cells in the cecum contents upon administration of propionate or butyrate, suggesting that SCFAs do not promote bacterial evasion from the gut lumen (S11A Fig). In contrast, bacterial loads in the cecum tissues, MLN, liver, and spleen in wild-type mice were significantly reduced upon administration of propionate or butyrate (S11A Fig). These effects of SCFAs were not observed in ASC−/− mice (S11B Fig).

Fig 4. SCFAs enhance host defense against S. Typhimurium infection in an ASC-dependent manner.

Fig 4

(A) SPF wild-type mice were cohoused with SPF ASC−/− mice at a 1:1 gender ratio for 7 days and then were infected with S. Typhimurium strain A. Survival of SPF wild-type (●) and SPF ASC−/− mice (■) infected with S. Typhimurium strain A (left panel). Survival of antibiotic-treated wild-type (●) and ASC−/− mice (■) infected with S. Typhimurium strain A (right panel). P-values were determined by the log-rank test (n = 6 per group). Data are listed in S1 Data. (B) Treatment scheme followed to analyze the effect of SCFA administration on the susceptibility of antibiotic-treated mice to S. Typhimurium strain A. SPF mice were given antibiotics for 4 weeks. SCFAs were given 1 week before S. Typhimurium strain A infection. The administration of antibiotics was stopped before S. Typhimurium strain A infection. (C and D) Effects of propionate, butyrate, and lactate on the survival of wild-type (C) and ASC−/− (D) mice infected with S. Typhimurium strain A. The mice were given antibiotics for 1 month prior to being given drinking water containing 300 mM propionate, 300 mM butyrate, or 300 mM lactate for 1 week. Then, mice were inoculated with S. Typhimurium (108 bacteria) orally. P-values were determined by the log-rank test (n = 6 per group). Data are listed in S1 Data. ASC, apoptosis-associated speck-like protein; S. Typhimurium, S. enterica serovar Typhimurium; SCFA, short-chain fatty acid; SPF, specific pathogen-free.

SCFAs recruit neutrophils into S. Typhimurium–infected cecal mucosa via an ASC-dependent mechanism

Acute inflammatory cell infiltration plays a critical role in innate immunity against invading pathogens [32,33]. Therefore, we examined the effects of SCFAs on the local population of inflammatory cells in the cecal mucosa of S. Typhimurium–infected mice. As shown in Fig 5A, S. Typhimurium infection induced inflammatory cell infiltration into the cecal mucosa in SPF wild-type mice. In contrast, in SPF ASC−/− mice infected with S. Typhimurium, inflammatory cell infiltration was not evident, indicating that ASC plays a critical role in inflammatory cell infiltration of the cecum (Fig 5A). Moreover, inflammatory cell infiltration was not induced by S. Typhimurium infection in antibiotic-treated wild-type mice (Fig 5B). Administration of propionate or butyrate induced inflammatory cell infiltration in response to S. Typhimurium infection in antibiotic-treated wild-type mice, but not ASC−/− mice (Fig 5B). The inflammatory infiltrate score of the hematoxylin–eosin (HE)-stained tissues was calculated according to a previously published method [34]. The inflammatory infiltrate scores in S. Typhimurium–infected wild-type mice given propionate or butyrate were significantly higher than in mice that had not been treated with SCFAs or in S. Typhimurium–infected ASC−/− mice (S12A Fig). To determine whether administration of SCFAs to SPF mice without S. Typhimurium infection induces inflammatory cell infiltration, cecum tissues from SCFA-treated SPF wild-type or ASC−/− mice without S. Typhimurium infection were analyzed. Inflammatory cell infiltration was not detected in the cecal mucosa or submucosa of either mouse strain, indicating that SCFAs do not induce cecal inflammation without notable pathogenic bacterial infection (S13 Fig). Propionate and butyrate induced the migration of macrophages (F4/80-positive cells) into the cecal mucosa and submucosa of wild-type mice infected with S. Typhimurium; in contrast, these effects were not observed in ASC−/− mice infected with S. Typhimurium (Fig 5C). The staining intensities of F4/80 in the cecal mucosa and submucosa of S. Typhimurium–infected wild-type mice given propionate or butyrate were significantly higher than in S. Typhimurium–infected wild-type mice without SCFA treatment or in S. Typhimurium–infected ASC−/− mice (S12B left panel Fig). Propionate and butyrate significantly enhanced IL-1β production in antibiotic-treated wild-type mice, but not ASC−/− mice (Fig 5D). Neutrophils, which are recruited by IL-1β, are critical innate immune cells for protecting the host against pathogens [32,33,35]. As shown in Fig 5C, propionate and butyrate induced the infiltration of neutrophils (Gr-1-positive cells) into the cecal mucosa and submucosa of wild-type, but not into those of ASC−/− mice infected with S. Typhimurium. The staining intensities of Gr-1 in the cecal mucosa and submucosa of S. Typhimurium–infected wild-type mice that were orally given propionate or butyrate were significantly higher than in S. Typhimurium–infected wild-type mice without SCFA treatment or in S. Typhimurium–infected ASC−/− mice (S12B right panel Fig). In agreement with the immunostaining results, the neutrophil marker Gr-1 was detected in cecal tissues of wild-type mice that were given propionate or butyrate, but not in those of ASC−/− mice (Fig 5E). These findings suggested that SCFAs induce neutrophil recruitment into the S. Typhimurium–infected cecal mucosa through ASC-mediated inflammasome activation. Whereas excessive ROS production by neutrophils might eliminate gut commensal bacteria that prevent the colonization and/or expansion of S. Typhimurium [15], rapid neutrophil infiltration efficiently prevents the spread of the pathogen [36]. Our results suggest that SCFAs promote the elimination of S. Typhimurium by efficiently promoting neutrophil infiltration of the cecal mucosa by enhancing inflammasome activation in macrophages.

Fig 5. SCFAs recruit neutrophils to S. Typhimurium–infected foci through ASC-dependent inflammasome activation.

Fig 5

(A and B) HE staining of cecum tissues from SPF wild-type or ASC−/− mice and antibiotic-treated wild-type and ASC−/− mice infected with S. Typhimurium strain A. Scale bars = 10 μm. (C) Cecal mucosa was immunostained with an anti-F4/80 or anti-Gr-1 antibody after infection with S. Typhimurium strain A. Scale bars = 100 μm. (D) IL-1β production in the cecum tissues was measured by ELISA. Data are the mean ± SD. *P < 0.05. Data are listed in S1 Data. (E) Detection of the neutrophil marker Gr-1 protein by western blotting. Cecum tissues were collected, homogenized, and analyzed by western blotting using anti-Gr-1 and anti-actin antibodies. ASC, apoptosis-associated speck-like protein; HE, hematoxylin–eosin; IL, interleukin; S. Typhimurium, S. enterica serovar Typhimurium; SCFA, short-chain fatty acid; SD, standard deviation; SPF, specific pathogen-free.

Macrophage activation is required for the protective effect of SCFAs against S. Typhimurium infection

To investigate the potential role of macrophages in the ASC-dependent host-protective effect of SCFAs, we administrated clodronate-encapsulated liposomes, which deplete macrophages in vivo, to SCFA-treated mice for 24 hours prior to S. Typhimurium infection. As shown in Fig 6A, the resistance against S. Typhimurium infection in SCFA-treated mice was significantly reduced upon clodronate-encapsulated liposome administration. Moreover, clodronate-encapsulated liposome administration abolished the SCFA-induced decrease in bacterial cell numbers in cecum tissues, MLN, liver, and spleen (Fig 6B). Under these circumstances, infiltration of macrophages (F4/80-positive cells) and neutrophils (Gr-1-positive cells) into S. Typhimurium–infected cecal mucosa were not detected (Fig 6C). In addition, enhanced IL-1β production induced by SCFAs was not observed in S. Typhimurium–infected cecal mucosa (Fig 6D). These findings suggested that SCFAs induce neutrophil recruitment into S. Typhimurium–infected cecal mucosa through ASC-mediated activation of the inflammasome of macrophages, and this potentiates pathogen elimination in the infected mucosa. To assess the localization of S. Typhimurium in the cecal tissues of mice administrated with clodronate-encapsulated liposomes, the cecal mucosa was immunostained for S. Typhimurium. Whereas colocalization of S. Typhimurium and infiltrating macrophages (F4/80-positive cells) was detected in the cecal mucosa of SPF mice that had not been administered clodronate-encapsulated liposomes, increased staining of S. Typhimurium in the extracellular space was observed in the cecal submucosa of SPF mice treated with clodronate-encapsulated liposomes (S14 Fig). This result indicates that S. Typhimurium can invade and replicate extracellularly in the cecal submucosa of mice without macrophages. S. Typhimurium is translocated from the gastrointestinal tract to the bloodstream by infected phagocytes including macrophages [37,38]. Our findings suggested that SCFAs enhance bacterial elimination in the cecal mucosa by inducing neutrophil infiltration through mechanisms involving ASC-activating macrophages and thereby restrict the systemic spreading of S. Typhimurium. To confirm this possibility, we examined whether SCFAs activate the macrophages in MLN and Peyer’s patches. IL-1β production in MLN and Peyer’s patches was not significantly enhanced, indicating that SCFAs do not promote bacterial killing in MLN and Peyer’s patches via an ASC-dependent mechanism (S15 Fig). These findings indicated that SCFA-induced ASC-dependent activation of macrophages in the cecal mucosa promotes bacterial elimination to limit bacterial dissemination from the gastrointestinal tract to systemic sites.

Fig 6. SCFAs exert host-protective effects in a macrophage-dependent manner.

Fig 6

Mice were given antibiotics for 1 month prior to being given drinking water containing 300 mM propionate or 300 mM butyrate for 1 week. Then, clodronate liposomes (56 mg per kg of body weight) were intraperitoneally administrated to the mice 24 hours prior to oral infection with S. Typhimurium (108 bacteria). (A) Effect of clodronate liposomes (macrophage-depleting agent) on the survival of propionate- or butyrate-administrated wild-type mice infected with S. Typhimurium strain A. P-values were determined by the log-rank test (n = 6 per group). Data are listed in S1 Data. (B) Bacterial counts in cecum tissues, MLN, liver, and spleen were determined 2 days after infection. Cecum contents and each tissue were homogenized in PBS, and then the homogenates were plated on the Salmonella Shigella selection agar (Difco SS agar) and CFU were counted. Bars indicate the mean (n = 6 per group). *P < 0.05, **P < 0.01. Data are listed in S1 Data. (C) Immunostaining of cecum tissues after infection with S. Typhimurium strain A using anti-F4/80 (macrophage marker) and anti-Gr-1 (neutrophil marker) antibodies. Scale bars = 100 μm. (D) IL-1β production in the cecum as measured by ELISA. Data are the mean ± SD. *P < 0.05, ** P < 0.01. Data are listed in S1 Data. CFU, colony-forming unit; DAPI, 4',6-diamidino-2-phenylindole; IL, interleukin; MLN, mesenteric lymph node; S. Typhimurium, S. enterica serovar Typhimurium; SCFA, short-chain fatty acid; SD, standard deviation.

Dietary fiber prevents S. Typhimurium infection through an ASC-dependent mechanism

Indigestible dietary fibers are fermented to SCFAs by gastrointestinal microorganisms and thus contribute to the SCFA concentration in the gut [39,40]. The effect of PHGG (mean molecular mass of 20 kDa [PHGG-R] or 14 kDa [PHGG-HG]), a water-soluble dietary fiber, on S. Typhimurium infection was examined. Administration of PHGG-R or PHGG-HG significantly increased the butyrate concentration in the cecum (Fig 7A). Administration of PHGG also prolonged the survival of S. Typhimurium–infected mice (Fig 7B). Enhanced resistance to S. Typhimurium infection induced by PHGG was not observed in ASC–/–mice, indicating that the protective effect of indigestible dietary fiber against the pathogen depends on ASC (Fig 7C). Administration of PHGG enhanced IL-1β production in S. Typhimurium–infected cecum tissues (Fig 7D). These results suggested that indigestible dietary fiber protects against S. Typhimurium infection by increasing butyrate production in the gut via an ASC-dependent mechanism.

Fig 7. Dietary fiber enhances host defense against S. Typhimurium infection.

Fig 7

(A) Dietary fiber (PHGG-R [mean molecular mass of 20 kDa] or PHGG-HG [mean molecular mass of 14 kDa]) was administered to SPF wild-type mice. Butyrate concentration in the cecal lumen as determined by LC-MS. Data are the mean ± SD (n = 5 per group). **P < 0.01. Data are listed in S1 Data. (B) Effect of each dietary fiber on the survival of wild-type infected with S. Typhimurium strain A (n = 6 per group). P-values were determined by the log-rank test. Data are listed in S1 Data. (C) Effect of each dietary fiber on the survival of ASC−/− mice infected with S. Typhimurium strain A (n = 5 per group). Data are listed in S1 Data. (D) IL-1β production in the cecum as determined by ELISA. Data are the mean ± SD. *P < 0.05. Data are listed in S1 Data. (E) Imaging mass spectrometric analysis of the localization of citrate, propionate, and butyrate/isobutyrate in cecum tissues from SPF wild-type mice (left panel), S. Typhimurium strain A–infected SPF wild-type mice (middle panel), and PHGGR-administrated S. Typhimurium strain A–infected SPF wild-type mice (right panel). Each tissue section was stained with HE (upper panel). Black dotted lines in imaging mass spectrometric images indicate a boundary between cecal lumen and cecal mucosa. Scale bars = 250 μm. ASC, apoptosis-associated speck-like protein; HE, hematoxylin–eosin; IL, interleukin; LC-MS, liquid chromatography–mass spectroscopy; PHGG, partially hydrolyzed guar gum; S. Typhimurium, S. enterica serovar Typhimurium; SD, standard deviation; SPF, specific pathogen-free.

SCFAs are difficult to visualize by conventional mass spectrometry with high-vacuum ionization system, because of their high volatility and low molecular mass. To overcome the technical difficulties, we utilized a high-resolution mass spectrometer using atmospheric-pressure ionization, which enabled us to stably detect SCFAs without sublimation. S. Typhimurium–infected cecal tissues lose structural stability owing to the inflammation, resulting in accidental cracks of the cecal mucosa and submucosa during the preparation of frozen sections. Despites this, the boundary between the cecal lumen and the mucosa could be identified in these sections and was indicated by a dotted line (Fig 7E). In SPF wild-type mice, normal cecal mucosal areas were abundant in citric acid, whereas only trace signals of propionate and butyrate were detected, indicating an intact mucosal barrier (Fig 7E left panel). In S. Typhimurium–infected SPF wild-type mice, marked accumulation of propionate and butyrate was observed in the inflamed cecal mucosa (Fig 7E middle panel). This regional distribution of SCFAs in the inflamed cecal mucosa suggested increased permeability of the damaged mucosa to SCFAs. Moreover, PHGG-R administration in S. Typhimurium–infected SPF wild-type mice enhanced regional access of propionate and butyrate into the inflamed cecal mucosa (Fig 7E right panel). These findings suggested that SCFAs produced from dietary fibers reach the nests of inflammatory cells infiltrating into the cecal mucosa and activate the inflammasomes of macrophages residing there.

Discussion

The inflammasome is a multimeric protein complex that consists of NLRPs, ASC, and caspase-1. Its activation leads to the production of mature proinflammatory cytokines IL-1β and IL-18 [41]. Chemical and biological approaches using high-performance affinity nanobeads revealed that SCFAs bind to the PYRIN domain of ASC and NLRP3 and thereby promote the activation of the inflammasome, resulting in inflammatory cytokine production, both in vitro and in vivo.

The inflammasome activation is caused by the formation of inflammasome complex by sensing danger signals including damage-associated molecular patterns (DAMPs) or pathogen-associated molecular patterns (PAMPs) by NLRPs. SCFAs did not induce the activation of inflammasome in macrophages without S. Typhimurium infection, indicating that enhanced activation of the inflammasome by SCFAs requires the sensing the DAMPs or PAMPs by NLRPs (Fig 3B, 3C and 3D). SCFAs promoted the binding of NLRPs to ASC by binding to the ASC PYRIN domain, resulting in the enhanced activation of inflammasome in response to PAMPs (Figs 1 and 2). The interaction between the PYRIN domains of ASC and NLRPs is required for activation of the inflammasome complex [20,21]. The PYRIN domain, which is composed of six helices, has distinct positively and negatively charged surface regions, and these bipolar surfaces are required for the binding between PYRIN domains [42]. Specifically, two basic residues within the ASC PYRIN domain (Lys21 and Arg41) are required for the interaction with the PYRIN domain of NLRPs [43]. We showed that SCFAs interact with the Lys-rich region of the ASC PYRIN domain, which includes the Lys21 residue, suggesting that SCFAs bind to the basic region of the PYRIN domain and alter electrostatic interactions, allowing it to more easily interact with other PYRIN domains. Lu and colleagues reported that the PYRIN and CARD domains of ASC are both filaments and that the PYRIN domain of ASC is nucleated by NLRP3, which senses PAMPs or DAMPs [44]. Although further investigation is needed to elucidate whether SCFAs affect the nucleation of the PYRIN domain of ASC filaments, our findings suggest that SCFAs promote the interaction of NLRPs with ASC by binding to the Lys-rich region of the ASC PYRIN domain, leading to enhanced inflammasome activation to protect against S. Typhimurium infection.

The Lys-rich region is highly conserved among PYRIN domain–containing proteins. Twenty-four PYRIN domain–containing proteins have been identified in humans to date, and they participate in apoptotic and inflammatory signaling pathways [42,45,46]. Further studies are necessary to unveil biological actions that result from SCFA binding to PYRIN domain–containing proteins other than the regulation of inflammasome activation as revealed in this study.

Although S. Typhimurium can metabolize butyrate by anaerobic β-oxidation because of its expression of the ydiQRSTD operon, which encodes metabolic enzymes related to β-oxidation of fatty acids [47], exposure to a high concentration of butyrate directly represses the expression of S. Typhimurium invasion genes (invA and hilD) [30,48,49]. Furthermore, Bronner and colleagues also showed that butyrate reduced S. Typhimurium colonization of Peyer’s patches by inducing down-regulation of these invasion genes [49]. In our analyses, the IL-1β production in Peyer’s patches was not enhanced by butyrate, suggesting that butyrate does not enhance inflammasome activation in Peyer’s patches via an ASC-dependent mechanism (S15 Fig). These results support the idea that reduced S. Typhimurium colonization of Peyer’s patches depends on the down-regulation of invasion gene expression by butyrate. On the other hand, in the cecum, our results show that butyrate enhanced IL-1β production via an ASC-dependent mechanism (Fig 5). Although further study is needed to elucidate the precise role of invasion genes in bacterial colonization, our findings indicate that butyrate enhances inflammasome activation to eliminate the bacteria in the cecum.

The SPI-1 of S. Typhimurium is known to induce the activation of the inflammasome, and therefore, in macrophages infected with S. Typhimurium SPI-1 deletion mutant strains, it has been reported that IL-1β production is small amounts and caspase-1 cleavage is undetectable [27,28]. Our results show that SCFAs enhanced LDH release and IL-1β production via an ASC-dependent mechanism in BMDMs infected with S. Typhimurium wild-type strain, leading to significantly less intracellular bacterial growth (Fig 3). On the other hand, SCFAs did not enhance the LDH release and IL-1β production in BMDMs without bacterial infection (Fig 3). From these results, SCFAs were conceivable to promote the inflammasome activation induced by SPI-1 through mechanisms involving binding to ASC in S. Typhimurium–infected macrophages. Whereas SCFAs enhanced IL-1β production in BMDMs infected with SPI-1 knock-down S. Typhimurium through an ASC-dependent mechanism, the levels of IL-1β production were lower compared with that of BMDMs infected with S. Typhimurium wild-type strains (Figs 3D and S6D). From these findings, it was thought that SCFAs cannot enhance the pyroptosis contributing to the reduction of intracellular bacterial growth in BMDMs infected with S. Typhimurium SPI-1 knock-down strains.

Inflammasome activation by SCFAs enhanced the elimination of S. Typhimurium in macrophages, and administration of propionate and butyrate protected mice against S. Typhimurium infection through mechanisms involving binding of SCFAs to ASC. Based on these results, we suggest a potential mechanism by which dietary fibers or SCFAs activate the inflammasome complex, as shown in Fig 8. SCFAs enhance inflammasome activation by binding to the Lys-rich region of ASC, which leads to IL-1β production and pyroptosis in macrophages. Intracellular S. Typhimurium were eliminated from macrophages by pyroptosis, and IL-1β induced the recruitment of neutrophils into S. Typhimurium–infected cecal mucosa. Notably, inflammasome activation by SCFAs occurred independently of the canonical SCFA receptor GPR43. In line with these results, Franchi and colleagues reported that neutrophil infiltration was defective in IL-1 receptor–deficient mice infected with S. Typhimurium [50]. Furthermore, systemic infection by S. Typhimurium was enhanced in neutrophil-depleted mice [50,51]. We also showed that administration of SCFAs or dietary fibers robustly enhanced inflammatory cell infiltration in the cecal mucosa in response to S. Typhimurium infection and suppressed bacterial systemic invasion. Imaging mass spectrometric analysis revealed that SCFAs accumulate in the region of the cecal mucosa where inflammation is induced by S. Typhimurium infection. Collectively, the results of the present study provide evidence for a novel mechanism by which SCFAs activate innate immune responses in the intestinal mucosa to prevent severe systemic infection by S. Typhimurium.

Fig 8. Schematic diagram of SCFA-induced inflammasome activation and defense against S. Typhimurium.

Fig 8

SCFAs, which are abundantly produced by fermentation of dietary fibers in the gut, induce inflammasome activation in infected macrophages by enhancing oligomerization of the inflammasome complex. Inflammasome activation contributes to the elimination of intracellular S. Typhimurium by pyroptosis. In addition, released pathogens are neutralized by infiltrating neutrophils, which are recruited to the inflamed tissue by IL-1β. ASC, apoptosis-associated speck-like protein; CARD, caspase activation and recruitment domain; IL, interleukin; LRR, leucine-rich repeat; NLRP, nucleotide-binding oligomerization domain-like receptor protein; PHGG, partially hydrolyzed guar gum; S. Typhimurium, S. enterica serovar Typhimurium; SCFA, short-chain fatty acid.

Our results show that gut commensal bacteria-derived SCFAs enhance cecal inflammation in S. Typhimurium–infected mice in an ASC-dependent manner. The concentrations of propionate and butyrate in the cecal lumen of the SPF-C57BL/6 mice used in this study were the same as those of antibiotic-treated mice given exogenous SCFAs, which also induced inflammation (S9 Fig). Therefore, the localization of these SCFAs in the cecal lumen of SPF-C57BL/6 mice is thought to induce inflammation in the cecum in response to S. Typhimurium infection (Fig 5A). On the other hand, Barthel and colleagues reported that S. Typhimurium infection in SPF mice did not lead to cecal inflammation [52]. SCFAs are metabolites of gut commensal bacteria, and therefore, the concentration of SCFAs in the gut depends on the composition of the gut microbiota. Thus, the induction of cecal inflammation in SPF mice infected with S. Typhimurium may depend on the composition of the gut microbiota. The composition of gut commensal bacteria is reported to be significantly different in mice obtained from different vendors [53]. Although further study is needed to clarify the composition profile of gut microbiota associated with the induction of cecal inflammation in response to S. Typhimurium infection, our findings show that SCFAs induce cecal inflammation, which contributes to protection against bacterial infection through an ASC-dependent mechanism.

The administration of dietary fiber prior to bacterial infection significantly prolonged the survival of S. Typhimurium–infected mice by increasing the production of butyrate. In human epidemiologic studies, Africans reportedly were less susceptible to pathogenic bacterial infections than Europeans because of the high levels of intestinal SCFAs owing to high dietary fiber intake [54]. However, the precise molecular mechanisms of the protective effects of dietary fiber intake against pathogenic infection had not been clarified. Our finding that SCFAs induced inflammasome activation supported these human epidemiological findings and provide evidence for the that fact dietary fiber intake can protect against gastrointestinal infections by activating innate immunity. Although further investigation is needed to grasp the precise mechanisms by which dietary fiber and SCFAs modulate intestinal infection, our findings provide new insights into potential therapeutic interventions to prevent pathogenic infections.

Materials and methods

Ethics statement

Animal care and use followed the regulations of the Act on Welfare and Management of Animals of Japan. All mice were bred and maintained under SPF conditions approved by Institutional Guidelines on Animal Experimentation at Keio University. All animal experiments were approved by the Keio University Animal Research Committee (no. 14016).

Materials and antibodies

LPS (Calbiochem, San Diego, CA, United States of America, cat. no. 437627), ATP (Sigma-Aldrich, St. Louis, MO, USA, cat. no. A26209), nigericin (Cayman, Ann Arbor, MI, USA, cat. no. 28643-80-3), Imject Alum Adjuvant (Thermo Fisher Scientific, Waltham, MA, USA, cat. no. 77161), and anthrax lethal toxin (Calbiochem, cat. no. 176900) were used as inflammasome activators. Acetate (cat. no. 017–00256), propionate (cat. no. 163–04726), butyrate (cat. no. 023–05396), and lactate (cat. no. 128–00056) were purchased from Wako (Tokyo, Japan). The PHGG (PHGG, guar fiber, and galactomannan fiber) preparation (Sunfiber) used in this study was obtained from Taiyo Kagaku (Yokkaichi, Japan). The preparation was manufactured by treatment of guar gum with β-endogalactomannase from a strain of Aspergillus niger. The average molecular masses of PHGG-R and PHGG-HG were determined to be 20 and 14 kDa, respectively, by high-performance liquid chromatography. The following antibodies were used for western blotting: anti-caspase-1 (p20) (AdipoGen, San Diego, CA, USA, cat. no. AG-20B-0042; 1:500), anti-F4/80 antigen (M-300) (Santa Cruz Biotechnology, Santa Cruz, CA, USA, cat. no. sc-25830; 1:500), anti-ASC (N-15) (Santa Cruz Biotechnology, cat no. sc-22514; 1:500), anti-Gr-1/Ly-6G (R&D Systems, Minneapolis, MN, USA, cat. no. MAB1037; 1:500), anti-GPR43 (Y-15) (Santa Cruz Biotechnology, cat. no. sc-28420; 1:500), anti-NLRP3 (Abcam, Cambridge, UK, cat. no. ab214185; 1:1,000), and anti-β-actin (Sigma-Aldrich, cat. no. A2228; 1:1,000). Anti-mouse F4/80 antigen (A3-1) (Bio-Rad, Hercules, CA, USA, cat. no. MCA497; 1:50), anti-Salmonella Typhimurium LPS (Abcam, cat. no. ab8274250), and anti-Gr-1/Ly-6G (R&D Systems; 1:50) were used for immunohistochemistry.

Cell and bacterial cultures

U937 cells (ATCC CRL-1593.2) were maintained in RPMI 1640 medium (Gibco/Thermo Fisher Scientific, cat. no. 11875093) supplemented with 10% fetal bovine serum (FBS). 293T cells (ATCC CRL-3216) were grown in Dulbecco’s modified Eagle’s medium (DMEM; Gibco, cat. no. 11965092) supplemented with 10% FBS. BMDMs were prepared by flushing bone marrow from femurs and tibiae with DMEM and were cultured in DMEM supplemented with 10% FBS and 20 ng/mL recombinant mouse macrophage-colony stimulating factor (PeproTech, Rocky Hill, NJ, USA, cat. no. 315–02) for 7 days. S. Typhimurium strain A (obtained from the Research Institute for Microbial Diseases bacterial culture collection of Osaka University, Japan) [55] and S. Typhimurium ATCC14028S strain were cultured on Luria–Bertani (LB) agar (Becton-Dickinson, Franklin Lakes, NJ, USA, cat. no. 743–29229) overnight at 37°C. S. Typhimurium strain A was used for in vitro analysis using BMDMs. S. Typhimurium strain A and ATCC14028S strain were used for in vivo analysis. Bacterial counts were determined by measuring the optical density of the bacterial suspension at 550 nm.

Construction of the S. Typhimurium SPI-1 knock-down mutant strain

SPI-1 knock-down bacteria were constructed with an in-frame deletion of sipB, a transcriptional activator of SPI-1. An Flp recombination target (FRT)-flanked chloramphenicol-resistant marker cassette (KD3) fragment was amplified using the primers 5′-GTGTAGGCTGGAGCTGCTTC-3′ (forward) and 5′-ATGGGAATTAGCCATGGTCC-3′ (reverse) [56], and the PCR products were inserted into pGFPmut 3.1 (Clonetech, cat. no. 632370) downstream of the gfp gene. The sipB::gfp-KD3 fragment was amplified using the primers 5′-CGGAGACAGAGCAGCACAGTGAACAAGAAAAGGAATAATTATGCGTAAAGGAGAAGAACT-3′ (forward) and 5′-TACTAATTAACATATTTTTCTCCCTTTATTTTGGCAGTTTGTGTAGGCTGGAGCTGCTTC (reverse). The PCR products of the sipB::gfp-KD3 fragment were introduced into S. Typhimurium SR-11 χ3306/pKD46 by electroporation to construct the sipB in-frame replacement strain of S. Typhimurium SR-11 χ3306. The in-frame sipB deletion on the chromosome of sipB::gfp-KD3 fragment-electroporated S. Typhimurium SR-11 χ3306 was accomplished by λ Red-mediated recombination [57].

Mice

All mice were bred and maintained under SPF conditions. All mice were fed the CE-2 diet (Japan Clea, Tokyo, Japan), which consists mainly of vegetable protein (soybean meal) and animal protein and contains a fiber source (wheat bran, defatted rice bran, and alfalfa meal). Male and female wild-type, ASC−/−, and GPRR43−/− mice were used for experiments. To match the gender in the experiment, 6-week-old C57BL/6J male mice were purchased from SLC Japan (Shizuoka, Japan). ASC−/− mice were generated by replacing a 1.9-kb fragment encoding the ASC open reading frame with nLacZ and floxed pMC1 neo poly(A) [58]. To confirm the deletion of ASC, a 350-bp fragment of the ASC gene was amplified from genomic DNA using the primers 5′-CCAGGTAATGGTTAATCCCAGCAACC-3′ (forward) and 5′-TTGGCATTGCATGACATGGTGCACAC-3′ (reverse). GPR43−/− mice were generated by CRISPR-Cas9 gene editing. A guide RNA (gRNA) was designed for exon 3 of GPR43 using the Optimized CRISPR Design tool (http://crispr.mit.edu/) (S4B Fig). The GPR43 gRNA was introduced into the pX330-U6-Chimeric_BB-CBh-hSpCas9 plasmid, and the gRNA expression vector was injected into the pronuclei of fertilized embryos collected from the oviducts of C57BL/6 mice. After injection, the zygotes were transferred into recipient females. To confirm the deletion of GPR43, a 390-bp fragment of the GPR43 gene was amplified from genomic DNA using the primers 5′-CAGACTGGCACAGTTCCTTGATCC-3′ (forward) and 5′-GCGATCACTCCATACAGTGGCC-3′ (reverse).

16S rRNA sequencing of microbiota and profile analysis

Fresh fecal samples were collected from five wild-type or ASC−/− mice, and genomic DNA was extracted using the NucleoSpin Microbial DNA Kit (TaKaRa, cat. no. U0235) according to the manufacturer’s instructions. The extracted genomic DNA was sent to Macrogen (Tokyo, Japan) for metagenomics sequencing. The sequencing library was prepared by random fragmentation of the DNA, followed by 5′ and 3′ adapter ligation using Herculase II fusion DNA polymerase (Agilent, cat. no. 600675) and Nextera XT Index Kit V2 (Illumina, cat. no. FC-131-1001), according Illumina’s guidelines for 16S metagenomic sequencing library preparation (Illumina, Part #15044223 Rev. B). The amplicon of 16S rRNA was sequenced using paired-end sequencing on the Illumina MiSeq platform. The sequences were clustered de novo into operational taxonomic units (OTUs) using a CD-HIT-EST-based OTU analysis program (CD-HIT-OTU) and a cutoff of >97% similarity. The Shannon diversity index and the Inverse Simpson index, which account for both richness and evenness, and in which an increased value indicates greater diversity, were used to compare the microbial diversity of the OTUs in the libraries. The PCoA analysis of the weighted UniFrac distances was applied to the distance matrices for visualization of the microbial diversity of the OTUs in the libraries.

Plasmid preparation

Full-length human ASC cDNA was amplified from a U937 cell cDNA library using the primers 5′-TTTTGAATTCATGGGGCGCGCGCGCGAC-3′ (forward) and 5′-TTTTGTCGACTCAGCTCCGCTCCAGGTCCTCCAC-3′ (reverse) and was introduced into the bacterial expression vector pGEX6P-1 (GE Healthcare, Waukesha, WI, USA, cat. no. 28954648). ASC deletion mutants (18 a.a. or 27 a.a.) were prepared using the primer 5′-TTTGAATTCGCCGAGGAGCTCAAGAAG-3′ for Δ18 and 5′-TTTGAATTCCTGTCGGTGCCGCTG-3′ for Δ27 and were introduced into pGEX6P-1. A FLAG-tagged ASC fragment was amplified using the primers 5′-TTTTGAATTCAATGGGGCGCGCGCGCGACGCC-3′ (forward) and 5′-TTTTAGATCTTCAGCTCCGCTCCAGGTCCTCCAC-3′ (reverse) and was introduced into pCMV10 (Sigma-Aldrich, cat. no. E7658). Human NLRP3 cDNA (OriGene, Rockville, MD, USA, cat. no. SC110747) was amplified using the primers 5′-TTTGGATCCATGAAGATGGCAAGCACCCGC-3′ (forward) and 5′-TTTCTCGAGCTACCAAGAAGGCTCAAAGAC-3′ (reverse) and was introduced into the mammalian expression vector pCDNA3.1 (Thermo Fisher Scientific, cat. no. V79020).

For the preparation of in vitro–translated proteins, full-length cDNAs of NLRP1, 3, 4, and 6, which were obtained from OriGene, were introduced into the SP6 promoter-containing vector pF3A WG Flexi (Promega, Madison, WI, USA, cat. no. L5671) using the following primers: NLRP1 forward, 5′-TTTTCGATACGCCATGGCTGGCGGAGCCTGGGGC-3′; NLRP1 reverse, 5′-TTTTGTTTAAACTCAGCTGCTGAGTGGCAGGAG-3′; NLRP3 forward, 5′-TTTTCGATACGCCATGAAGATGGCAAGCACCCGC-3′; NLRP3 reverse, 5′-TTTTGTTTAAACTTACTTCGGCTCATCTCTTTTTGCTTT-3′; NLRP4 forward, 5′-TTTTCGATACGCCATGGCAGCCTCTTTCTTCTCT-3′; NLRP4 reverse, 5′-TTTTGTTTAAACTCAGATCTCTACCCTTGTGAT-3′; NLRP6 forward, 5′-TTTTCGATACGCCATGGACCAGCCAGAGGCCCCC-3′; and NLRP6 reverse, 5′-TTTTGTTTAAACTCAGAAGGTCGAGATGAGTTCC-3′.

Preparation of recombinant proteins

BL21 (DE3) cells were transformed with the pGEX-ASC expression vectors for full-length ASC or deletion mutants and were cultured in LB with ampicillin at 37°C until an optical density at 600 nm (OD600 nm) of 0.8 was reached. Protein expression was induced by the addition of 1 mM isopropyl-β-thiogalactopyranoside at 37°C for 4 hours. Cell pellets were resuspended in buffer containing 20 mM Tris-HCl (pH 7.5), 100 mM NaCl, and 0.1% Tween-20, sonicated twice for 5 minutes at 4°C, and centrifuged at 20,000g for 30 minutes. The supernatant was incubated with Glutathione Sepharose 4B (GE Healthcare, cat. no. 17075601) at 4°C for 1 hour. Then, the resin was washed five times with the above buffer, the GST tag was cleaved by the addition of Precision Protease (GE Healthcare, cat. no. 27084301), and the sample was incubated at 4°C for another 16 hours. Cleaved proteins were recovered from the supernatants and stored at –80°C.

For the preparation of in vitro–translated proteins, vectors expressing NLRP1, 3, 4, or 6 under the control of an SP6 promoter (5 μg) were incubated with 50 μL of TNT SP6 High-Yield Wheat Germ Protein Expression System (Promega, cat. no. L3260) and fluorescently labeled using FluoroTect GreenLys in vitro Translation Labeling System (Promega, cat. no. L5001) according to the manufacturer’s instructions.

Affinity purification using SCFA-conjugated affinity beads

For the preparation of SCFA-conjugated affinity beads, amino-modified affinity beads [16] were incubated with 1 mM succinate anhydride, malate anhydride, or glutarate anhydride in N,N-dimethylformamide at room temperature overnight. The conjugated beads were washed three times with N,N-dimethylformamide, and unreacted amine groups on the beads were masked by incubation with 5% acetic anhydride for 4 hours.

For the purification of SCFA-binding proteins, 0.2 mg of beads was equilibrated with binding buffer (20 mM HEPES-NaOH [pH 7.9], 100 mM NaCl, 10% glycerol, 1 mM EDTA, 0.1% NP-40) and incubated with 1 mg/mL U937 cell extract at 4°C for 1 hour. Bound proteins were eluted with sodium dodecyl sulfate (SDS) loading buffer, separated by SDS–polyacrylamide gel electrophoresis (PAGE), and visualized by silver staining (Wako, cat. no. 291–50301). Bound proteins were subjected to in-gel digestion with trypsin, and the peptide fragments were analyzed by ESI-MS (Hitachi, NanoFrontier, Tokyo, Japan).

For binding assays with recombinant ASC proteins, full-length ASC or deletion mutants (1 μg) were incubated with SCFA-conjugated beads, and binding was analyzed as described above. For competition assays, full-length ASC protein was preincubated with the indicated amount of propionate, butyrate, or lactate for 30 minutes, and then binding assays were performed.

In vitro binding assay for NLRP3 and ASC

GST or GST-ASC (10 μg) was incubated with 10 μL of Glutathione Sepharose Beads (GE Healthcare) for 1 hour, and the beads were washed twice with PBS. The GST-ASC-immobilized resin was incubated with fluorescently labeled NLRP3 in 500 μL of binding buffer (20 mM HEPES-NaOH [pH 7.9], 100 mM NaCl, 10% glycerol, 1 mM EDTA, 0.1% NP40) with the indicated amounts of propionate, butyrate, or lactate for 1 hour. Bound proteins were washed three times with binding buffer and subjected to SDS-PAGE. Labeled NLRP3 protein was detected using a fluorescence imager (Typhoon FLA 9500; GE Healthcare), and GST or GST-ASC protein was visualized by Coomassie Brilliant Blue staining.

Coimmunoprecipitation assays

FLAG-ASC (4 μg) and/or NLRP3 (8 μg) expression vectors were transfected into 293T cells using Lipofectamine 2000 (Invitrogen/Thermo Fisher Scientific, cat. no. 11668027) according to the manufacturer’s instructions. The cells were incubated with the indicated amounts of propionate, butyrate, or lactate for 24 hours and then lysed with NP-40 lysis buffer (20 mM Tris-HCl [pH 7.5], 150 mM NaCl, 1% NP40). The lysates were incubated with 10 μL of equilibrated anti-FLAG (M2) agarose beads (Sigma-Aldrich, cat. no. A2220) at room temperature for 1 hour. Bound proteins were washed three times with 200 μl of binding buffer and eluted with 10 μL of 2 μg/mL FLAG peptide (Sigma-Aldrich, cat. no. F3290). The eluates were subjected to SDS-PAGE and visualized by western blotting using antibody against FLAG (Sigma-Aldrich, cat. no. F3040) or NLRP3 (Abcam).

Cytokine measurement in U937 cells

U937 cells were seeded in 96-well plates and stimulated by the addition of 100 nM phorbol myristate acetate (Sigma-Aldrich, cat. no. P8139) for 24 hours. Then, the cells were treated with LPS (100 ng/mL) and ATP (5 μM), LPS and nigericin (5 μM), alum adjuvant (300 μg/mL), or anthrax lethal toxin (1 μg/mL) in the presence of the indicated concentrations of propionate, butyrate, or lactate for 12 hours. Cell culture supernatants were collected, and IL-1β (R&D Systems, cat. no. DLB50) and IL-18 (R&D Systems, cat. no. DL180) production was measured by ELISA according to the manufacturer’s instructions.

S. Typhimurium infection of BMDMs

BMDMs were seeded into 24- or 96-well plates at 2 × 105 or 5 × 104 cells per well. The cells were primed with 1 μg/mL LPS for 3 hours prior to S. Typhimurium strain A infection to induce pro-IL-1β expression. S. Typhimurium strain A cells were resuspended in DMEM. BMDMs were incubated with S. Typhimurium strain A at a multiplicity of infection of 5 for 10 minutes and then washed three times with PBS and incubated in DMEM containing 100 μg/mL gentamycin for 15 hours with or without SCFAs at a concentration of 1–10 mM. The cells were washed with PBS and lysed with PBS containing 1% Triton X-100. The cell lysates were plated on LB agar, and surviving intracellular S. Typhimurium strain A were enumerated as colony-forming units. IL-1β release in the cell culture supernatants was quantified using a mouse IL-1β ELISA kit (Abcam, ab100704) according to the manufacturer’s instructions. LDH release was quantified using the CytoTox 96 cytotoxicity assay kit (Promega, G1780) according to the manufacturer’s protocol. The percent LDH release was calculated as the ratio of the amount of LDH released under each experimental condition to the amount of LDH released by cells treated with 0.8% TritonX, as follows: % LDH release = [experimental LDH release (OD490) − average LDH release in cells treated with culture medium (OD490)]/[LDH release in cells treated with 0.8% TritonX-100 (OD490) − average LDH release in cells treated with culture medium (OD490)] × 100. Mature caspase-1 subunits are released into the supernatant in response to inflammasome activation [59]; therefore, to detect cleaved caspase-1 p20, cell culture supernatants were precipitated with 10% trichloroacetic acid on ice for 1 hour and then centrifuged at 10,000g at 4°C for 30 minutes. Precipitated proteins eluted in SDS loading buffer were subjected to SDS-PAGE and visualized by western blotting using an anti-caspase-1 antibody (AdipoGen). BMDMs were incubated with the MCT inhibitor SR13800 (Calbiochem, 509663) for 24 hours prior to S. Typhimurium strain A infection.

Quantitative reverse transcription–polymerase chain reaction (RT-qPCR)

S. Typhimurium strain A were cultured in the presence of 10 mM acetate, propionate, butyrate, or lactate in LB broth overnight at 37°C, with agitation. Total RNA was isolated using the SV Total RNA Isolation System (Promega, Fitchburg, WI, USA, Z3100) and reverse-transcribed using the PrimeScript RT Reagent Kit (TaKaRa, Ohtsu, Japan, RR037A). PCRs were run using TB Green Premix Ex Taq II (TaKaRa, RR820S) in a Dice thermal cycler (TaKaRa, Ohtsu, Japan). The following primers were used: 16S rRNA mRNA, forward 5′-TGTTGTGGTTAATAACCGCA and reverse 5′-GACTACCAGGGTATCTAATCC; fliB mRNA, forward 5′-CTACGCGCTTCAGACAGATT and reverse 5′-GATCTGGGTGCGGTACAAA; fliC mRNA, forward 5′-GTAACGCTAACGACGGTATC and reverse 5′-ATTTCAGCCTGGATGGAGTC; sipD mRNA, forward 5′-TGAAAACGTTGTCGCAGTCT and reverse 5′-GCGCTGGAAATAAAACGGTA; prgH mRNA, forward 5′-AGATACGTTGTGGGCTCGTC and reverse 5′-TTCTTGCTCATCGTGTTTCG [60].

S. Typhimurium infection of mice

All animal studies were approved by the Keio University Animal Research Committee (no. 14016). SPF wild-type mice were cohoused with SPF ASC−/− mice at a 1:1 gender ratio for 7 days prior to S. Typhimurium infection [61]. To clarify the role of SCFAs in the protection against S. Typhimurium infection, it was important to exclude the effects of endogenous SCFAs by completely eradicating gut commensal bacteria. Rakoff-Nahoum and colleagues reported that the combination therapy of four antibiotics (ampicillin, metronidazole, neomycin, and vancomycin) for mice was used for complete depletion of gut commensal bacteria [62]. Therefore, to exclude the effects of endogenous SCFAs derived from gut microbiota, 8- to 10-week-old mice were given drinking water containing ampicillin (1 g/L; Sigma-Aldrich, cat. no. A0166), metronidazole (1 g/L; Sigma-Aldrich, cat. no. M1547), neomycin (1 g/L; Sigma-Aldrich, cat. no. N1876), and vancomycin (0.5 g/L; Wako, cat. no. 222–01303) for 4 weeks prior to S. Typhimurium infection, as previously described [62,63]. Mice that lost more than 20% of their body weight by refusing to drink the antibiotic cocktail were excluded from experimental use, following the guidelines of the Keio University Animal Research Committee. The administration of antibiotics was stopped before bacterial infection. The mice were then given drinking water containing 300 mM SCFAs (propionate or butyrate) or 300 mM lactate for 1 week, according to a published protocol [64]. Since exogenous SCFAs were administrated to antibiotic-treated mice in the drinking water, the concentrations of SCFAs in the cecal lumen were variable at the time of killing depending on the length of time since water intake. Therefore, the concentrations of SCFAs in the cecal lumen of mice were measured after an oral boost with 100 μL of 300 mM propionate or butyrate 2 hours prior to killing. S. Typhimurium (108 bacteria) were inoculated orally to the mice [65], and then survival was monitored daily. To assess the bacterial counts in the liver, spleen, and intestines, mice inoculated orally with S. Typhimurium (2 × 106 bacteria) were humanely killed 2 days post infection, and the indicated tissues were collected and homogenized in PBS with Qiagen TissueLyser (Qiagen, Valencia, CA, USA). Serial dilutions of the homogenates were plated on the selection medium Difco SS agar (BD Pharmingen, cat. no. 274500) and colony-forming units were counted. For analysis of the effect of dietary fiber, PHGG (5 g per kg of body weight per day) was orally administered to mice for 3 weeks prior to S. Typhimurium infection, and survival was monitored. For analysis of the effect of macrophages, clodronate liposomes (FormuMax, Sunnyvale, CA, USA, F70101C-A) was intraperitoneally administered (56 mg per kg of body weight) to mice for 24 hours prior to S. Typhimurium infection to deplete macrophages. To determine sample size, a pilot study (n = 6) was performed to estimate the significant effect size of SCFAs, PHGG, or clodronate liposomes on S. Typhimurium infection in mouse. This estimated effect size (n  =  6) gave a significant effect of SCFAs, PHGG, or clodronate liposomes on S. Typhimurium infection. This sample size was also used for no-statistical experiments.

Histopathology of S. Typhimurium–infected mice

Cecum samples from mice infected with S. Typhimurium (2 × 106 cells) for 2 days were collected, fixed in 4% paraformaldehyde overnight, and embedded in paraffin. Tissue sections (4 μm) were depleted of paraffin, rehydrated in a series of graded ethanol solutions, and stained with HE. HE-stained sections were observed using a NanoZoomer-XR (Hamamatsu Photonics, Tokyo, Japan). The inflammatory infiltrate score of HE-stained specimens were calculated based on the inflammatory infiltrate score defined by Koelink and colleagues’ report [34]. For immunohistochemistry, tissue sections were subjected to antigen retrieval by heating for at 105°C in Target Retrieval Solution (pH 9) (Dako, S2375) for 10 minutes. The tissue sections were then incubated with antibody against F4/80 antigen (Bio-Rad) or Gr-1 (R&D Systems) at 4°C overnight and then with 4',6-diamidino-2-phenylindole (DAPI; 1 μg/mL) and an Alexa Fluor 488–conjugated anti-rat or anti-goat IgG secondary antibody for 1 hour. Fluorescence images were obtained using an LSM710 confocal microscope (Carl Zeiss, Oberkochen, Germany). The staining quantifications of F4/80 and Gr-1 in the S. Typhimurium–infected cecum tissues were performed using ImageJ analysis software (National Institutes of Health, Bethesda, MD, USA). For the detection of IL-1β and Gr-1 in tissue, cecum samples were homogenized in RIPA buffer containing protease inhibitors. IL-1β was detected using a mouse IL-1β ELISA kit (Abcam, ab100704). Gr-1 expression was detected by western blotting using an anti-Gr-1 antibody (R&D Systems).

Measurement of SCFAs

SCFAs were quantified by liquid chromatography–ESI-tandem MS (LC-ESI-MS/MS) with chemical derivatization [66,67]. Fecal samples (2–8 mg) were collected and suspended in 0.3 ml of EtOH with an internal standard (2-ethylbutyric acid). After centrifugation, SCFAs in the supernatant were derivatized with 2-nitrophenylhydrazine (2-NPH; at a final concentration of 10 mM), 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide hydrochloride (10 mM), and 1.5% pyridine in 75% MeOH at room temperature for 30 minutes, with shaking. Aliquots were diluted 5-fold with 75% MeOH containing 0.5% formic acid and then subjected to LC-ESI-MS/MS. LC separation was conducted on a Mastro C18 column (2.1 mm I.D. × 150 mm L, 3 μm; Shimadzu, Kyoto, Japan) with a Nexera ultrahigh-performance liquid chromatography system (Shimadzu). The mobile phase consisted of 0.1% formic acid in water (A) and acetonitrile (B). The column oven temperature was maintained at 40°C. The LC system was coupled with an LCMS-8060 triple-quadruple mass spectrometer (Shimadzu) operated in positive ion mode and multiple reaction monitoring mode with the following ion transitions: 2-NPH-derivatized acetate, m/z 196.3>43.1; derivatized propionate, m/z 210.1>57.2; derivatized butyrate and isobutyrate, m/z 224.2>71.1; derivatized valeric acid and isovaleric acid, m/z 238.1>85.1; 2-ethylbutyric acid (IS), m/z 252.2>99.2.

Imaging mass spectrometry

Cecum samples from SPF wild-type mice, SPF wild-type mice infected with S. Typhimurium (2 × 106 cells) for 2 days, and SPF wild-type mice administered PHGG-R (5 g per kg of body weight per day) for 3 weeks prior to S. Typhimurium infection were collected and embedded in the frozen embedding agent SCEM (Leica Microsystems, Tokyo Japan). Matrix-assisted laser desorption/ionization imaging analyses were performed as described previously [68]. Briefly, thin sections (8 μm) of the frozen-embedded caecum tissues were prepared with a cryo-microtome (CM3050; Leica Microsystems, Tokyo, Japan). The sections were attached onto indium tin oxide–coated glass slides (Bruker Daltonics GmbH, Leipzig, Germany) and were coated with 9-aminoacridine as the matrix (10 mg/mL, dissolved in 80% ethanol) by manual spraying with an airbrush (Procon Boy FWA Platinum; Mr. Hobby, Tokyo, Japan). The matrix was simultaneously applied to multiple sections in order to maintain consistent analyte extraction and co-crystallization conditions. Data were acquired using an orbitrap mass spectrometer (QExactive Focus; Thermo Fisher Scientific) coupled with an atmospheric-pressure scanning microprobe matrix-assisted laser desorption/ionization ion source (AP-SMALDI10; TransMIT GmbH, Giessen, Germany). The raster step size was set at 50 μm. For the orbitrap mass spectrometer, signals within a mass range of 50–192 were acquired with a mass resolving power of 70,000 at m/z 200, which enables calculation of the specific chemical formula of each ion signal. The spectral data were transformed to image data and analyzed using ImageQuest 1.0.1 (Thermo Fisher Scientific) and SCiLS 2019a (Bruker Daltonics) software.

Statistical analysis

Data are presented as the mean ± standard deviation (SD). Means of multiple groups were compared by analysis of variance (ANOVA) followed by Tukey’s tests using JSTAT statistical software (version 8.2). Animals were randomly assigned among the various groups. In repeated immunostaining experiments, conditions were randomized to account for potential ordering effects. All analyses were conducted with blinding to the experimental condition. Cumulative survival rates were analyzed by the Kaplan–Meier method, and differences in survival between subgroups were detected by log-rank testing using SPSS, version 22 for Windows (SPSS, Chicago, IL, USA). P < 0.05 was considered significant.

Supporting information

S1 Fig. SCFAs enhance IL-1β production induced by NLRP activators.

IL-1β production in U937 cells stimulated with SCFAs and LPS/nigericin, alum adjuvant, or lethal toxin as measured by ELISA. Data are the mean ± SD of three independent assays. One-way ANOVA analysis, *P < 0.05, **P < 0.01. Data are listed in S1 Data. ANOVA, analysis of variance; IL, interleukin; LPS, lipopolysaccharide; NLRP, nucleotide-binding oligomerization domain-like receptor protein; SCFA, short-chain fatty acid; SD, standard deviation.

(TIF)

S2 Fig. Structures of fatty-acid derivatives, including mono-fatty acids, branched carboxylic acids, and di- and tri-carboxylic acids.

(TIF)

S3 Fig. Time-course analysis of inflammasome activation by SCFAs in S. Typhimurium–infected BMDMs.

(A) BMDMs derived from wild-type mice were infected with S. Typhimurium strain A at multiplicity of infection of 5 for 10 minutes and then incubated in DMEM containing 100 μg/mL gentamycin for the indicated time with or without treatment with 10 mM acetate (Ace), propionate (Pro), butyrate (But), or lactate (Lac). Bacterial cell numbers within BMDMs are shown. Data are the mean ± SD of three independent assays. One-way ANOVA analysis, *P < 0.05 versus nontreated BMDMs (ctrl). Data are listed in S1 Data. (B and C) IL-1β production and LDH release in cell-culture media as determined by LDH assay and ELISA, respectively. Data are the mean ± SD of three independent assays. One-way ANOVA analysis, **P < 0.01 versus nontreated BMDMs (ctrl). Data listed in S1 Data. ANOVA, analysis of variance; BMDM, bone marrow–derived macrophage; DMEM, Dulbecco’s modified Eagle’s medium; IL, interleukin; LDH, lactate dehydrogenase; ND, not detected (below the detection limit); S. Typhimurium, S. enterica serovar Typhimurium; SCFA, short-chain fatty acid; SD, standard deviation.

(TIF)

S4 Fig. BMDMs derived from ASC- or GPR43-deficient mice.

(A) PCR analysis of ASC (350-bp PCR product) in genomic DNA isolated from wild-type or ASC–/–mice (left panel). The expression of ASC and F4/80, a macrophage marker, in the bone marrow or in BMDMs derived from wild-type or ASC–/–mice was analyzed by western blotting (right panel). (B) GPR43-deficient mice were generated using CRISPR-Cas9 gene editing. Cas9/gRNA-targeting sites in GPR43. Exons are indicated by closed boxes, and the boxed sequence begins 60 bp from the start codon and contains the targeting sequence in the coding region of exon 3. The gRNA-targeting sequence is underlined, and the PAM sequences are indicated in red. The CRISPR-Cas9 incision site is indicated by an arrow. (C) PCR analysis of GPR43 (390-bp PCR product) in genomic DNA isolated from wild-type or GPR43–/–mice (left panel). GPR43 expression in BMDMs derived from wild-type or GPR43–/–mice was analyzed by western blotting (right panel). ASC, apoptosis-associated speck-like protein; BMDM, bone marrow–derived macrophage; CRISPR-Cas9, clustered regularly interspersed short palindromic repeats–CRISPR-associated protein 9; gRNA, guide RNA; PAM, protospacer adjacent motif; PCR, polymerase chain reaction.

(TIF)

S5 Fig. SCFAs do not directly affect S. Typhimurium.

(A) S. Typhimurium strain A was cultured in LB broth containing 10 mM SCFAs (acetate, propionate, butyrate, or lactate) for the indicated times at 37°C, with agitation. Bacterial growth was monitored by measuring the optical density at 550 nm. Data are listed in S1 Data. (B) Effects of SCFAs on the expression of two flagellin genes of S. Typhimurium strain A. mRNA expression of fliC and fliB was measured by RT-qPCR. Data are the mean ± SD of three independent assays. Data are listed in S1 Data. LB, Luria–Bertani; RT-qPCR, quantitative reverse transcription–polymerase chain reaction; S. Typhimurium, S. enterica serovar Typhimurium; SCFA, short-chain fatty acid; SD, standard deviation.

(TIF)

S6 Fig. Effect of SCFAs on inflammasome activation in macrophages infected with an S. Typhimurium SPI-1 knock-down mutant.

(A) Effects of SCFAs on the expression of SPI-1 genes (sipD and prgH) by S. Typhimurium. The expression of sipD and prgH in S. Typhimurium strain A and the S. Typhimurium SPI-1 knock-down strain were measured by RT-qPCR after SCFA exposure. Data are the mean ± SD of three independent assays. Student's t test, *P < 0.05, **P < 0.01. Data are listed in S1 Data. (B) BMDMs derived from wild-type or ASC−/− mice were infected with SPI-1 knock-down S. Typhimurium at a multiplicity of infection of 5 for 10 minutes and then were incubated in DMEM containing 100 μg/mL gentamycin for 15 hours with or without treatment with acetate (Ace), propionate (Pro), butyrate (But), or lactate (Lac). The percentages of surviving S. Typhimurium SPI-1 knock-down bacteria in SCFA-treated macrophages is shown relative to the survival in untreated macrophages (ctrl). Data are the mean ± SD of three independent assays. Data are listed in S1 Data. (C and D) BMDMs derived from wild-type or ASC−/− mice were infected with SPI-1 knock-down S. Typhimurium at a multiplicity of infection of 5 for 10 minutes and then were incubated in DMEM containing 100 μg/mL gentamycin for 15 hours with or without treatment with 10 mM acetate (Ace), 10 mM propionate (Pro), 10 mM butyrate (But), or 10 mM lactate (Lac). Cell supernatants were collected, and LDH release and IL-1β production were determined by LDH assay and ELISA, respectively. Data are the mean ± SD of three independent assays. One-way ANOVA analysis, *P < 0.05. Data are listed in S1 Data. ANOVA, analysis of variance; BMDM, bone marrow–derived macrophage; DMEM, Dulbecco’s modified Eagle’s medium; LDH, lactate dehydrogenase; ND, not detected (below the detection limit); NS, not significant; RT-qPCR, quantitative reverse transcription–polymerase chain reaction; S. Typhimurium, S. enterica serovar Typhimurium; SCFA, short-chain fatty acid; SD, standard deviation; SPI-1, Salmonella pathogenicity island 1.

(TIF)

S7 Fig. Pathogenicity of S. Typhimurium strain A and ATCC14028S strain against mice.

(A) Survival of SPF wild-type mice infected with S. Typhimurium strain A (108 bacteria) (black circle) and infected with S. Typhimurium ATCC14028S strain (108 bacteria) (blue circle). n = 6 per group. Data listed in S1 Data. (B) HE staining of cecum tissues from SPF wild-type infected with S. Typhimurium strain A or S. Typhimurium ATCC14028S strain. Scale bars = 50 μm. HE, hematoxylin–eosin; S. Typhimurium, S. enterica serovar Typhimurium; SPF, specific pathogen-free.

(TIF)

S8 Fig. Gut microbial diversity analysis of wild-type or ASC−/− mice.

(A) The Shannon diversity index and the Inverse Simpson index were analyzed to compare the microbial diversity between wild-type and ASC−/− mice. The box-and-whisker plots show the full range of variation, the interquartile ranges, and the median values. The data points indicate the diversity indices of each mouse. Data are listed in S1 Data. (B) The two principal coordinates from the PCoA of the weighted UniFrac distances were plotted to the distance matrices for visualization of the microbial diversity. The data points indicate each mouse. Data are listed in S1 Data. ASC, apoptosis-associated speck-like protein; PCoA, principal coordinate analysis.

(TIF)

S9 Fig. Effect of antibiotics administration on the concentrations of propionate, butyrate, and lactate in the cecal lumen.

Mice were given drinking water containing ampicillin (1 g/L), metronidazole (1 g/L), neomycin (1 g/L), and vancomycin (0.5 g/L). After 4 weeks, the mice were humanely killed and cecum samples were collected. Antibiotic-treated mice were given drinking water containing 300 mM propionate, butyrate, or lactate for 1 week, and cecum samples were collected following a boost with propionate, butyrate, and lactate 2 hours prior to killing. n = 5 per group. One-way ANOVA analysis, **P < 0.01. Data are listed in S1 Data. ND, not detected (below the detection limit).

(TIF)

S10 Fig. Propionate and butyrate improve the survival of GPR43−/− mice infected with S. Typhimurium.

GRP43–/–mice treated or not with propionate (n = 7 mice per group) or butyrate (n = 6 mice per group) were infected orally with 108 S. Typhimurium, and survival was monitored. P-values were determined by the log-rank test. Data are listed in S1 Data. S. Typhimurium, S. enterica serovar Typhimurium.

(TIF)

S11 Fig. Effects of propionate, butyrate, or lactate on the S. Typhimurium–infected bacterial number in wild-type and ASC−/− mice.

(A and B) Bacterial cells in the cecum contents, cecum tissues, MLN, liver, and spleen were counted 2 days after infection. Cecum contents and each tissue were homogenized in PBS, and then the homogenates were plated on the Salmonella Shigella selection agar (Difco SS agar) and colony-forming units were counted. Bars indicate the mean (n = 6 per group). One-way ANOVA analysis, *P < 0.05, **P < 0.01. Data are listed in S1 Data. ANOVA, analysis of variance; ASC, apoptosis-associated speck-like protein; MLN, mesenteric lymph node; S. Typhimurium, S. enterica serovar Typhimurium.

(TIF)

S12 Fig. The inflammatory infiltrate score and the staining intensity in S. Typhimurium–infected cecal mucosa and submucosa of wild-type or ASC−/− mice.

(A) The inflammatory infiltrate scores of HE-stained specimens were calculated. Bars indicate the mean (n = 6 per group). One-way ANOVA analysis, *P < 0.05, **P < 0.01. Data are listed in S1 Data. (B) The staining intensities for F4/80 and Gr-1 in the S. Typhimurium–infected cecum tissues of wild-type or ASC−/− mice were quantified using ImageJ analysis software. Bars indicate the mean (n = 6 per group). One-way ANOVA analysis, *P < 0.05. Data are listed in S1 Data. ANOVA, analysis of variance; ASC, apoptosis-associated speck-like protein; HE, hematoxylin–eosin; S. Typhimurium, S. enterica serovar Typhimurium.

(TIF)

S13 Fig. The effect of SCFA treatment on SPF mice without S. Typhimurium infection.

HE staining of cecum tissues from SCFAs-treated SPF wild-type or SPF ASC−/− mice without S. Typhimurium infection. Scale bars = 100 μm. ASC, apoptosis-associated speck-like protein; HE, hematoxylin–eosin; S. Typhimurium, S. enterica serovar Typhimurium; SCFA, short-chain fatty acid; SPF, specific pathogen-free.

(TIF)

S14 Fig. Detection of S. Typhimurium in the cecal mucosa and submucosa of mice administered clodronate-encapsulated liposomes.

Immunostaining of cecum tissues using an anti-F4/80 antibody and an anti–S. Typhimurium LPS antibody. Scale bars = 50 μm. S. Typhimurium, S. enterica serovar Typhimurium.

(TIF)

S15 Fig. SCFAs does not activate macrophages in MLN and Peyer's patches through an ASC-dependent mechanism.

(A) IL-1β production in MLN as determined by ELISA (n = 4 per group). (B) IL-1β production in Peyer’s patches as determined by ELISA (n = 4 per group). Data are listed in S1 Data. ASC, apoptosis-associated speck-like protein; IL, interleukin; MLN, mesenteric lymph node; ND, not detected (below the detection limit).

(TIF)

Acknowledgments

We are grateful to the Collaborative Research Resources, Keio University School of Medicine, for technical assistance.

Abbreviations

a.a.

amino acid

ASC

apoptosis-associated speck-like protein

BMDM

bone marrow–derived macrophage

CARD

caspase activation and recruitment domain

CRISPR-Cas9

clustered regularly interspersed short palindromic repeats–CRISPR-associated protein 9

DAMP

damage-associated molecular pattern

ESI-MS

electrospray ionization–mass spectroscopy

GST

glutathione-S-transferase

HE

hematoxylin–eosin

IL

interleukin

LDH

lactate dehydrogenase

LPS

lipopolysaccharide

Lys

lysine

MCT

monocarboxylate transporter

MLN

mesenteric lymph node

NLRP

nucleotide-binding oligomerization domain-like receptor protein

PAMP

pathogen-associated molecular pattern

PCoA

principal coordinate analysis

PHGG

partially hydrolyzed guar gum

S. Typhimurium

S. enterica serovar Typhimurium

SCFA

short-chain fatty acid

SPF

specific pathogen-free

SPI-1

Salmonella pathogenicity island 1

Data Availability

All data can be found in the Supporting information (S1 Data).

Funding Statement

This work was supported by AMED-CREST from the Japan Agency for Medical Research and Development, AMED (to YK, grant no.: JP17gm0710010). The S. Typhimurium infection model in this work was partly supported by Cross-ministerial Strategic Innovation Promotion Program (SIP), “Technologies for creating next-generation agriculture, forestry and fisheries” (funding agency: Bio-oriented Technology Research Advancement Institution, NARO) (to HT). Infrastructures for imaging mass spectrometry and metabolomics were supported in part by Ryoshoku-Kenkyukai and JST ERATO Suematsu Gas Biology Project (M.S.) until FY2015. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

References

  • 1.Collins SM, Surette M, Bercik P. The interplay between the intestinal microbiota and the brain. Nat Rev Microbiol. 2012;10(11):735–42. 10.1038/nrmicro2876 . [DOI] [PubMed] [Google Scholar]
  • 2.Macfarlane S, Macfarlane GT. Regulation of short-chain fatty acid production. Proc Nutr Soc. 2003;62(1):67–72. 10.1079/PNS2002207 . [DOI] [PubMed] [Google Scholar]
  • 3.Buffie CG, Pamer EG. Microbiota-mediated colonization resistance against intestinal pathogens. Nat Rev Immunol. 2013;13(11):790–801. 10.1038/nri3535 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 4.Desai MS, Seekatz AM, Koropatkin NM, Kamada N, Hickey CA, Wolter M, et al. A Dietary Fiber-Deprived Gut Microbiota Degrades the Colonic Mucus Barrier and Enhances Pathogen Susceptibility. Cell. 2016;167(5):1339–53 e21. 10.1016/j.cell.2016.10.043 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 5.Ishihara N, Chu DC, Akachi S, Juneja LR. Preventive effect of partially hydrolyzed guar gum on infection of Salmonella enteritidis in young and laying hens. Poult Sci. 2000;79(5):689–97. 10.1093/ps/79.5.689 . [DOI] [PubMed] [Google Scholar]
  • 6.Rios-Covian D, Ruas-Madiedo P, Margolles A, Gueimonde M, de Los Reyes-Gavilan CG, Salazar N. Intestinal Short Chain Fatty Acids and their Link with Diet and Human Health. Front Microbiol. 2016;7:185 10.3389/fmicb.2016.00185 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 7.Tolhurst G, Heffron H, Lam YS, Parker HE, Habib AM, Diakogiannaki E, et al. Short-chain fatty acids stimulate glucagon-like peptide-1 secretion via the G-protein-coupled receptor FFAR2. Diabetes. 2012;61(2):364–71. 10.2337/db11-1019 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 8.Kimura I, Ozawa K, Inoue D, Imamura T, Kimura K, Maeda T, et al. The gut microbiota suppresses insulin-mediated fat accumulation via the short-chain fatty acid receptor GPR43. Nat Commun. 2013;4:1829 10.1038/ncomms2852 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 9.Boffa LC, Vidali G, Mann RS, Allfrey VG. Suppression of histone deacetylation in vivo and in vitro by sodium butyrate. J Biol Chem. 1978;253(10):3364–6. . [PubMed] [Google Scholar]
  • 10.Schilderink R, Verseijden C, Seppen J, Muncan V, van den Brink GR, Lambers TT, et al. The SCFA butyrate stimulates the epithelial production of retinoic acid via inhibition of epithelial HDAC. Am J Physiol Gastrointest Liver Physiol. 2016;310(11):G1138–46. 10.1152/ajpgi.00411.2015 . [DOI] [PubMed] [Google Scholar]
  • 11.Schauber J, Iffland K, Frisch S, Kudlich T, Schmausser B, Eck M, et al. Histone-deacetylase inhibitors induce the cathelicidin LL-37 in gastrointestinal cells. Mol Immunol. 2004;41(9):847–54. 10.1016/j.molimm.2004.05.005 . [DOI] [PubMed] [Google Scholar]
  • 12.Furusawa Y, Obata Y, Fukuda S, Endo TA, Nakato G, Takahashi D, et al. Commensal microbe-derived butyrate induces the differentiation of colonic regulatory T cells. Nature. 2013;504(7480):446–50. 10.1038/nature12721 . [DOI] [PubMed] [Google Scholar]
  • 13.Nakao S, Moriya Y, Furuyama S, Niederman R, Sugiya H. Propionic acid stimulates superoxide generation in human neutrophils. Cell Biol Int. 1998;22(5):331–7. 10.1006/cbir.1998.0263 . [DOI] [PubMed] [Google Scholar]
  • 14.Vinolo MA, Rodrigues HG, Nachbar RT, Curi R. Regulation of inflammation by short chain fatty acids. Nutrients. 2011;3(10):858–76. 10.3390/nu3100858 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 15.Rivera-Chavez F, Zhang LF, Faber F, Lopez CA, Byndloss MX, Olsan EE, et al. Depletion of Butyrate-Producing Clostridia from the Gut Microbiota Drives an Aerobic Luminal Expansion of Salmonella. Cell Host Microbe. 2016;19(4):443–54. 10.1016/j.chom.2016.03.004 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 16.Sakamoto S, Kabe Y, Hatakeyama M, Yamaguchi Y, Handa H. Development and application of high-performance affinity beads: toward chemical biology and drug discovery. Chem Rec. 2009;9(1):66–85. 10.1002/tcr.20170 . [DOI] [PubMed] [Google Scholar]
  • 17.Kabe Y, Nakane T, Koike I, Yamamoto T, Sugiura Y, Harada E, et al. Haem-dependent dimerization of PGRMC1/Sigma-2 receptor facilitates cancer proliferation and chemoresistance. Nat Commun. 2016;7:11030 10.1038/ncomms11030 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 18.Mariathasan S, Monack DM. Inflammasome adaptors and sensors: intracellular regulators of infection and inflammation. Nat Rev Immunol. 2007;7(1):31–40. 10.1038/nri1997 . [DOI] [PubMed] [Google Scholar]
  • 19.Petrilli V, Dostert C, Muruve DA, Tschopp J. The inflammasome: a danger sensing complex triggering innate immunity. Curr Opin Immunol. 2007;19(6):615–22. 10.1016/j.coi.2007.09.002 . [DOI] [PubMed] [Google Scholar]
  • 20.Masumoto J, Taniguchi S, Nakayama J, Shiohara M, Hidaka E, Katsuyama T, et al. Expression of apoptosis-associated speck-like protein containing a caspase recruitment domain, a pyrin N-terminal homology domain-containing protein, in normal human tissues. J Histochem Cytochem. 2001;49(10):1269–75. 10.1177/002215540104901009 . [DOI] [PubMed] [Google Scholar]
  • 21.Srinivasula SM, Poyet JL, Razmara M, Datta P, Zhang Z, Alnemri ES. The PYRIN-CARD protein ASC is an activating adaptor for caspase-1. J Biol Chem. 2002;277(24):21119–22. 10.1074/jbc.C200179200 . [DOI] [PubMed] [Google Scholar]
  • 22.Brown AJ, Goldsworthy SM, Barnes AA, Eilert MM, Tcheang L, Daniels D, et al. The Orphan G protein-coupled receptors GPR41 and GPR43 are activated by propionate and other short chain carboxylic acids. J Biol Chem. 2003;278(13):11312–9. 10.1074/jbc.M211609200 . [DOI] [PubMed] [Google Scholar]
  • 23.Samuvel DJ, Sundararaj KP, Nareika A, Lopes-Virella MF, Huang Y. Lactate boosts TLR4 signaling and NF-kappaB pathway-mediated gene transcription in macrophages via monocarboxylate transporters and MD-2 up-regulation. J Immunol. 2009;182(4):2476–84. 10.4049/jimmunol.0802059 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 24.Welter H, Claus R. Expression of the monocarboxylate transporter 1 (MCT1) in cells of the porcine intestine. Cell Biol Int. 2008;32(6):638–45. 10.1016/j.cellbi.2008.01.008 . [DOI] [PubMed] [Google Scholar]
  • 25.Murray CM, Hutchinson R, Bantick JR, Belfield GP, Benjamin AD, Brazma D, et al. Monocarboxylate transporter MCT1 is a target for immunosuppression. Nature Chemical Biology. 2005;1(7):371–6. 10.1038/nchembio744 [DOI] [PubMed] [Google Scholar]
  • 26.Franchi L, Amer A, Body-Malapel M, Kanneganti TD, Ozoren N, Jagirdar R, et al. Cytosolic flagellin requires Ipaf for activation of caspase-1 and interleukin 1beta in salmonella-infected macrophages. Nat Immunol. 2006;7(6):576–82. 10.1038/ni1346 . [DOI] [PubMed] [Google Scholar]
  • 27.Miao EA, Alpuche-Aranda CM, Dors M, Clark AE, Bader MW, Miller SI, et al. Cytoplasmic flagellin activates caspase-1 and secretion of interleukin 1beta via Ipaf. Nat Immunol. 2006;7(6):569–75. 10.1038/ni1344 . [DOI] [PubMed] [Google Scholar]
  • 28.Franchi L. Role of inflammasomes in salmonella infection. Front Microbiol. 2011;2:8 10.3389/fmicb.2011.00008 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 29.Sun YH, Rolan HG, Tsolis RM. Injection of flagellin into the host cell cytosol by Salmonella enterica serotype Typhimurium. J Biol Chem. 2007;282(47):33897–901. 10.1074/jbc.C700181200 . [DOI] [PubMed] [Google Scholar]
  • 30.Lawhon SD, Maurer R, Suyemoto M, Altier C. Intestinal short-chain fatty acids alter Salmonella typhimurium invasion gene expression and virulence through BarA/SirA. Mol Microbiol. 2002;46(5):1451–64. 10.1046/j.1365-2958.2002.03268.x . [DOI] [PubMed] [Google Scholar]
  • 31.Garner CD, Antonopoulos DA, Wagner B, Duhamel GE, Keresztes I, Ross DA, et al. Perturbation of the small intestine microbial ecology by streptomycin alters pathology in a Salmonella enterica serovar typhimurium murine model of infection. Infect Immun. 2009;77(7):2691–702. 10.1128/IAI.01570-08 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 32.Basset C, Holton J, O'Mahony R, Roitt I. Innate immunity and pathogen-host interaction. Vaccine. 2003;21 Suppl 2:S12–23. . [DOI] [PubMed] [Google Scholar]
  • 33.Iwasaki A, Medzhitov R. Toll-like receptor control of the adaptive immune responses. Nat Immunol. 2004;5(10):987–95. 10.1038/ni1112 . [DOI] [PubMed] [Google Scholar]
  • 34.Koelink PJ, Wildenberg ME, Stitt LW, Feagan BG, Koldijk M, van 't Wout AB, et al. Development of Reliable, Valid and Responsive Scoring Systems for Endoscopy and Histology in Animal Models for Inflammatory Bowel Disease. J Crohns Colitis. 2018;12(7):794–803. 10.1093/ecco-jcc/jjy035 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 35.Miller LS, Pietras EM, Uricchio LH, Hirano K, Rao S, Lin H, et al. Inflammasome-mediated production of IL-1beta is required for neutrophil recruitment against Staphylococcus aureus in vivo. J Immunol. 2007;179(10):6933–42. . [DOI] [PubMed] [Google Scholar]
  • 36.Cheminay C, Chakravortty D, Hensel M. Role of neutrophils in murine salmonellosis. Infect Immun. 2004;72(1):468–77. 10.1128/iai.72.1.468-477.2004 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 37.Vazquez-Torres A, Jones-Carson J, Baumler AJ, Falkow S, Valdivia R, Brown W, et al. Extraintestinal dissemination of Salmonella by CD18-expressing phagocytes. Nature. 1999;401(6755):804–8. 10.1038/44593 . [DOI] [PubMed] [Google Scholar]
  • 38.Worley MJ, Nieman GS, Geddes K, Heffron F. Salmonella typhimurium disseminates within its host by manipulating the motility of infected cells. Proc Natl Acad Sci U S A. 2006;103(47):17915–20. 10.1073/pnas.0604054103 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 39.Anderson JW, Bridges SR. Short-chain fatty acid fermentation products of plant fiber affect glucose metabolism of isolated rat hepatocytes. Proc Soc Exp Biol Med. 1984;177(2):372–6. . [DOI] [PubMed] [Google Scholar]
  • 40.Boillot J, Alamowitch C, Berger AM, Luo J, Bruzzo F, Bornet FR, et al. Effects of dietary propionate on hepatic glucose production, whole-body glucose utilization, carbohydrate and lipid metabolism in normal rats. Br J Nutr. 1995;73(2):241–51. . [DOI] [PubMed] [Google Scholar]
  • 41.Schroder K, Tschopp J. The inflammasomes. Cell. 2010;140(6):821–32. 10.1016/j.cell.2010.01.040 . [DOI] [PubMed] [Google Scholar]
  • 42.Liepinsh E, Barbals R, Dahl E, Sharipo A, Staub E, Otting G. The death-domain fold of the ASC PYRIN domain, presenting a basis for PYRIN/PYRIN recognition. J Mol Biol. 2003;332(5):1155–63. . [DOI] [PubMed] [Google Scholar]
  • 43.Vajjhala PR, Mirams RE, Hill JM. Multiple binding sites on the pyrin domain of ASC protein allow self-association and interaction with NLRP3 protein. J Biol Chem. 2012;287(50):41732–43. 10.1074/jbc.M112.381228 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 44.Lu A, Magupalli VG, Ruan J, Yin Q, Atianand MK, Vos MR, et al. Unified polymerization mechanism for the assembly of ASC-dependent inflammasomes. Cell. 2014;156(6):1193–206. 10.1016/j.cell.2014.02.008 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 45.Fairbrother WJ, Gordon NC, Humke EW, O'Rourke KM, Starovasnik MA, Yin JP, et al. The PYRIN domain: a member of the death domain-fold superfamily. Protein Sci. 2001;10(9):1911–8. 10.1110/ps.13801 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 46.Martinon F, Hofmann K, Tschopp J. The pyrin domain: a possible member of the death domain-fold family implicated in apoptosis and inflammation. Curr Biol. 2001;11(4):R118–20. . [DOI] [PubMed] [Google Scholar]
  • 47.Campbell JW, Morgan-Kiss RM, Cronan JE Jr., A new Escherichia coli metabolic competency: growth on fatty acids by a novel anaerobic beta-oxidation pathway. Mol Microbiol. 2003;47(3):793–805. 10.1046/j.1365-2958.2003.03341.x . [DOI] [PubMed] [Google Scholar]
  • 48.Gantois I, Ducatelle R, Pasmans F, Haesebrouck F, Hautefort I, Thompson A, et al. Butyrate specifically down-regulates salmonella pathogenicity island 1 gene expression. Appl Environ Microbiol. 2006;72(1):946–9. 10.1128/AEM.72.1.946-949.2006 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 49.Bronner DN, Faber F, Olsan EE, Byndloss MX, Sayed NA, Xu G, et al. Genetic Ablation of Butyrate Utilization Attenuates Gastrointestinal Salmonella Disease. Cell Host Microbe. 2018;23(2):266–73 e4. 10.1016/j.chom.2018.01.004 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 50.Franchi L, Kamada N, Nakamura Y, Burberry A, Kuffa P, Suzuki S, et al. NLRC4-driven production of IL-1beta discriminates between pathogenic and commensal bacteria and promotes host intestinal defense. Nat Immunol. 2012;13(5):449–56. 10.1038/ni.2263 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 51.Croswell A, Amir E, Teggatz P, Barman M, Salzman NH. Prolonged impact of antibiotics on intestinal microbial ecology and susceptibility to enteric Salmonella infection. Infect Immun. 2009;77(7):2741–53. 10.1128/IAI.00006-09 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 52.Barthel M, Hapfelmeier S, Quintanilla-Martinez L, Kremer M, Rohde M, Hogardt M, et al. Pretreatment of mice with streptomycin provides a Salmonella enterica serovar Typhimurium colitis model that allows analysis of both pathogen and host. Infect Immun. 2003;71(5):2839–58. 10.1128/iai.71.5.2839-2858.2003 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 53.Hufeldt MR, Nielsen DS, Vogensen FK, Midtvedt T, Hansen AK. Variation in the gut microbiota of laboratory mice is related to both genetic and environmental factors. Comp Med. 2010;60(5):336–47. [PMC free article] [PubMed] [Google Scholar]
  • 54.De Filippo C, Cavalieri D, Di Paola M, Ramazzotti M, Poullet JB, Massart S, et al. Impact of diet in shaping gut microbiota revealed by a comparative study in children from Europe and rural Africa. Proc Natl Acad Sci U S A. 2010;107(33):14691–6. 10.1073/pnas.1005963107 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 55.Atarashi K, Nishimura J, Shima T, Umesaki Y, Yamamoto M, Onoue M, et al. ATP drives lamina propria T(H)17 cell differentiation. Nature. 2008;455(7214):808–12. 10.1038/nature07240 . [DOI] [PubMed] [Google Scholar]
  • 56.Matsui H, Fukiya S, Kodama-Akaboshi C, Eguchi M, Yamamoto T. Mouse models for assessing the cross-protective efficacy of oral non-typhoidal Salmonella vaccine candidates harbouring in-frame deletions of the ATP-dependent protease lon and other genes. J Med Microbiol. 2015;64(Pt 3):295–302. 10.1099/jmm.0.000014 . [DOI] [PubMed] [Google Scholar]
  • 57.Datsenko KA, Wanner BL. One-step inactivation of chromosomal genes in Escherichia coli K-12 using PCR products. Proc Natl Acad Sci U S A. 2000;97(12):6640–5. 10.1073/pnas.120163297 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 58.Yamamoto M, Yaginuma K, Tsutsui H, Sagara J, Guan X, Seki E, et al. ASC is essential for LPS-induced activation of procaspase-1 independently of TLR-associated signal adaptor molecules. Genes Cells. 2004;9(11):1055–67. 10.1111/j.1365-2443.2004.00789.x . [DOI] [PubMed] [Google Scholar]
  • 59.Laliberte RE, Eggler J, Gabel CA. ATP treatment of human monocytes promotes caspase-1 maturation and externalization. J Biol Chem. 1999;274(52):36944–51. 10.1074/jbc.274.52.36944 . [DOI] [PubMed] [Google Scholar]
  • 60.Eakley NM, Bochsler PN, Gopal Reddy P, Chopra AK, Fadl AA. Biological and virulence characteristics of the YqhC mutant of Salmonella. Microbiol Immunol. 2011;55(12):830–40. 10.1111/j.1348-0421.2011.00387.x . [DOI] [PubMed] [Google Scholar]
  • 61.Wesemann DR, Portuguese AJ, Meyers RM, Gallagher MP, Cluff-Jones K, Magee JM, et al. Microbial colonization influences early B-lineage development in the gut lamina propria. Nature. 2013;501(7465):112–5. 10.1038/nature12496 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 62.Rakoff-Nahoum S, Paglino J, Eslami-Varzaneh F, Edberg S, Medzhitov R. Recognition of commensal microflora by toll-like receptors is required for intestinal homeostasis. Cell. 2004;118(2):229–41. 10.1016/j.cell.2004.07.002 . [DOI] [PubMed] [Google Scholar]
  • 63.Hall JA, Bouladoux N, Sun CM, Wohlfert EA, Blank RB, Zhu Q, et al. Commensal DNA limits regulatory T cell conversion and is a natural adjuvant of intestinal immune responses. Immunity. 2008;29(4):637–49. 10.1016/j.immuni.2008.08.009 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 64.Chang PV, Hao L, Offermanns S, Medzhitov R. The microbial metabolite butyrate regulates intestinal macrophage function via histone deacetylase inhibition. Proc Natl Acad Sci U S A. 2014;111(6):2247–52. 10.1073/pnas.1322269111 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 65.Broz P, Newton K, Lamkanfi M, Mariathasan S, Dixit VM, Monack DM. Redundant roles for inflammasome receptors NLRP3 and NLRC4 in host defense against Salmonella. J Exp Med. 2010;207(8):1745–55. 10.1084/jem.20100257 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 66.Miwa H, Yamamoto M. High-performance liquid chromatographic analysis of serum short-chain fatty acids by direct derivatization. J Chromatogr. 1987;421(1):33–41. . [DOI] [PubMed] [Google Scholar]
  • 67.Narushima S, Sugiura Y, Oshima K, Atarashi K, Hattori M, Suematsu M, et al. Characterization of the 17 strains of regulatory T cell-inducing human-derived Clostridia. Gut Microbes. 2014;5(3):333–9. 10.4161/gmic.28572 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 68.Sugiura Y, Katsumata Y, Sano M, Honda K, Kajimura M, Fukuda K, et al. Visualization of in vivo metabolic flows reveals accelerated utilization of glucose and lactate in penumbra of ischemic heart. Sci Rep. 2016;6:32361 10.1038/srep32361 [DOI] [PMC free article] [PubMed] [Google Scholar]

Decision Letter 0

Lauren A Richardson

7 Feb 2020

Dear Dr Kabe,

Thank you for submitting your manuscript entitled "Short-chain fatty acids bind to apoptosis-associated speck-like protein to activate inflammasome complex to prevent Salmonella infection" for consideration as a Research Article by PLOS Biology.

Your manuscript has now been evaluated by the PLOS Biology editorial staff as well as by an academic editor with relevant expertise and I am writing to let you know that we would like to send your submission out for external peer review.

However, before we can send your manuscript to reviewers, we need you to complete your submission by providing the metadata that is required for full assessment. To this end, please login to Editorial Manager where you will find the paper in the 'Submissions Needing Revisions' folder on your homepage. Please click 'Revise Submission' from the Action Links and complete all additional questions in the submission questionnaire.

Please re-submit your manuscript within two working days, i.e. by Feb 09 2020 11:59PM.

Login to Editorial Manager here: https://www.editorialmanager.com/pbiology

During resubmission, you will be invited to opt-in to posting your pre-review manuscript as a bioRxiv preprint. Visit http://journals.plos.org/plosbiology/s/preprints for full details. If you consent to posting your current manuscript as a preprint, please upload a single Preprint PDF when you re-submit.

Once your full submission is complete, your paper will undergo a series of checks in preparation for peer review. Once your manuscript has passed all checks it will be sent out for review.

Feel free to email us at plosbiology@plos.org if you have any queries relating to your submission.

Kind regards,

Lauren A Richardson, Ph.D

Senior Editor

PLOS Biology

Decision Letter 1

Di Jiang, PhD

16 Mar 2020

Dear Dr Kabe,

Thank you very much for submitting your manuscript "Short-chain fatty acids bind to apoptosis-associated speck-like protein to activate inflammasome complex to prevent Salmonella infection" for consideration as a Research Article at PLOS Biology. Your manuscript has been evaluated by the PLOS Biology editors, an Academic Editor with relevant expertise, and by two independent reviewers.

In light of the reviews (below), we will not be able to accept the current version of the manuscript, but we would welcome re-submission of a much-revised version that addresses all of the reviewers' concerns. We cannot make any decision about publication until we have seen the revised manuscript and your response to the reviewers' comments. Your revised manuscript is also likely to be sent for further evaluation by the reviewers.

We expect to receive your revised manuscript within 2 months.

Please email us (plosbiology@plos.org) if you have any questions or concerns, or would like to request an extension. At this stage, your manuscript remains formally under active consideration at our journal; please notify us by email if you do not intend to submit a revision so that we may end consideration of the manuscript at PLOS Biology.

**IMPORTANT - SUBMITTING YOUR REVISION**

Your revisions should address the specific points made by each reviewer. Please submit the following files along with your revised manuscript:

1. A 'Response to Reviewers' file - this should detail your responses to the editorial requests, present a point-by-point response to all of the reviewers' comments, and indicate the changes made to the manuscript.

*NOTE: In your point by point response to the reviewers, please provide the full context of each review. Do not selectively quote paragraphs or sentences to reply to. The entire set of reviewer comments should be present in full and each specific point should be responded to individually, point by point.

You should also cite any additional relevant literature that has been published since the original submission and mention any additional citations in your response.

2. In addition to a clean copy of the manuscript, please also upload a 'track-changes' version of your manuscript that specifies the edits made. This should be uploaded as a "Related" file type.

*Re-submission Checklist*

When you are ready to resubmit your revised manuscript, please refer to this re-submission checklist: https://plos.io/Biology_Checklist

To submit a revised version of your manuscript, please go to https://www.editorialmanager.com/pbiology/ and log in as an Author. Click the link labelled 'Submissions Needing Revision' where you will find your submission record.

Please make sure to read the following important policies and guidelines while preparing your revision:

*Published Peer Review*

Please note while forming your response, if your article is accepted, you may have the opportunity to make the peer review history publicly available. The record will include editor decision letters (with reviews) and your responses to reviewer comments. If eligible, we will contact you to opt in or out. Please see here for more details:

https://blogs.plos.org/plos/2019/05/plos-journals-now-open-for-published-peer-review/

*PLOS Data Policy*

Please note that as a condition of publication PLOS' data policy (http://journals.plos.org/plosbiology/s/data-availability) requires that you make available all data used to draw the conclusions arrived at in your manuscript. If you have not already done so, you must include any data used in your manuscript either in appropriate repositories, within the body of the manuscript, or as supporting information (N.B. this includes any numerical values that were used to generate graphs, histograms etc.). For an example see here: http://www.plosbiology.org/article/info%3Adoi%2F10.1371%2Fjournal.pbio.1001908#s5

*Blot and Gel Data Policy*

We require the original, uncropped and minimally adjusted images supporting all blot and gel results reported in an article's figures or Supporting Information files. We will require these files before a manuscript can be accepted so please prepare them now, if you have not already uploaded them. Please carefully read our guidelines for how to prepare and upload this data: https://journals.plos.org/plosbiology/s/figures#loc-blot-and-gel-reporting-requirements

*Protocols deposition*

To enhance the reproducibility of your results, we recommend that if applicable you deposit your laboratory protocols in protocols.io, where a protocol can be assigned its own identifier (DOI) such that it can be cited independently in the future. For instructions see: https://journals.plos.org/plosbiology/s/submission-guidelines#loc-materials-and-methods

Thank you again for your submission to our journal. We hope that our editorial process has been constructive thus far, and we welcome your feedback at any time. Please don't hesitate to contact us if you have any questions or comments.

Sincerely,

Di Jiang, PhD

Senior Editor

PLOS Biology

*****************************************************

REVIEWS:

Reviewer #1: Short chain fatty acids have been of continued interest due to their various effects on the microbiota and the host. The presented study by Tsugawa et al. sheds light on the mechanism of how SCFAs modulate the immune response and prolong survival after Salmonella infection. The authors determined that SCFAs bind to a lysine-rich domain of ASC, which facilitates binding to NLRPs. Macrophages exposed to SCFAs killed Salmonella more efficiently in vitro. In vivo, SCFA administration to antibiotics-treated mice increased their survival. No increased survival was seen for SCFA administration to ASC-/- mice. Administration of soluble fiber increased survival of Salmonella-infected mice.

This manuscript uncovers an interesting mechanism that should be of interest to a broad audience, as SCFA-mediated enhancement of the immune response will likely occur also with other intestinal pathogens. The experiments were in general performed rigorously and include important controls. The authors used a variety of different methods, including imaging mass spectrometry, to support their hypothesis. However, for some experimental assays, additional information and clarifications need to be provided.

The manuscript has two main weaknesses: 1) co-housing instead of using littermates and the lack of microbiota analysis and 2) no experimentation to exclude that added SCFAs regulate virulence gene expression in Salmonella.

Co-housing apparently rendered the observed phenotype in Fig. 1 less pronounced. The microbiota analysis would, especially as fiber fermentation is subject of analysis, be a valuable addition to the paper. It could help dispel concerns that phenotypes are due to microbiota difference not resolved during co-housing. A number of studies have shown that SCFAs modulate Salmonella virulence gene expression. This was not addressed experimentally or discussed.

The authors should address the following points:

1) Include analysis of the microbiota to show that WT and ASC-/- mouse microbiota is highly similar before the start of the experiment and during recovery. If there are differences before, differences in the microbiota that recovers after the stop of antibiotic treatment could be partially responsible for the observed phenotype.

2) Related to point 1: The experimental setup in 4B is unclear. Please indicate with horizontal bars the periods when the antibiotic cocktail was administered and when SCFAs were administered. Was administration of the cocktail stopped before Salmonella infection or was a resistant Salmonella strain used?

3) The authors did not indicate for how long they co-housed the mice. Extensive co-housing is accepted by researchers as a way to normalize the microbiota of strains of different origins. However, the authors used male mice for their experiments, where co-housing would presumably result in severe aggression. Please indicate for how long mice were co-housed and how they were housed during experiments (single vs. group).

4) SCFAs like butyrate and propionate are known to down-regulate Salmonella SPI-1 expression at higher concentrations. Experiments with ASC-/- mice and BMDM seem to indicate that this is not a relevant mechanism in this model. No actual numbers, just percentages are given, so it is difficult to interpret. A probably relevant control would be an experiment with a SPI-1 deficient Salmonella strain and WT and ASC-/- BDMDs.

5) Are the pictures in Fig. 5B truly representative? The immune cell recruitment with SCFAs is massive. Fig. 5C shows more moderate recruitment. Please provide pathology scores to assess all and not just representative mice.

6) Were all experiments done exclusively with male mice? The purchased C57BL/6 mice were male, but no indication for other strains is given. Ideally (and most often now requested) experiments should be performed with male and female mice to exclude gender bias.

Minor comments:

Manuscript is well written, but it needs to be thoroughly checked (e.g. "% of survive" or "infection to wild-type mice" and "scarify" in Fig. 4).

Multiple mouse models exist for Salmonella Typhimurium. Please provide the rationale for the choice of the mouse model you use (e.g. lower colonization and cecum inflammation than streptomycin pre-treatment mouse model).

M&M clarifications needed:

* Fiber and composition of the diet is important for the observed phenotype. Please indicate which diet the mice were fed.

* Mice are known to avoid drinking the antibiotic cocktail. How much weight did they lose before the beginning of the experiment? This should be noted to orient the reader to the fact that there are more differences between SPF and antibiotics-treated mice than the presence or absence of bacteria.

* The Salmonella strain used is likely ATCC 14028S and not ATCC 14208S?

* Rationale for using U937 cells, mention also in results.

* Some key information, e.g. how long BMDMs were incubated with Salmonella, is only available in the figure legend and not in the M&M. Please add where appropriate.

Fig. 3: Percent of LDH release is compared to which positive control?

Fig. 7: Imaging mass spectrometry is a very useful tool to illustrate the penetration of SCFAs into the tissue. In uninfected mice, the cecal tissue is easily identified, and also in sections of the infected mice. However, there seems to be absolutely no structure in the remaining parts, rather only huge rips. Are these artefacts from processing? Please explain this a bit more.

Fig. 3E: Why are here CFU/ml and not CFU as percent of control? How did this assay differ from the other similar assays in Fig. 3?

Fig. 3D: Please indicated that levels were below limit of detection and are not missing data

Fig. S4E: I assume you have done multiple tests to confirm the deletion, but this WB does not look convincing.

Fig. S7: Why was the extra SCFA boost necessary? Lines 252-254 seems to indicate that SCFA administration in the drinking water increases SCFA levels to similar levels as in SPF mice. However, the authors seem to measure an undefined boost and not what is available during Salmonella infection.

Fig. S9: Bacterial numbers recovered from mice usually have log-normal distribution and are best displayed on a log scale.

Reviewer #2: Tsugawa et al provide evidence for an interesting model in which short chain fatty acids (SCFAs), which are produced through fermentation of dietary fiber by members of the gut microbiota, facilitate the interaction between the inflammasome pattern recognition receptor Nlrp3 and its adaptor Asc, leading to enhanced inflammasome activation. The authors pinpoint a lysine rich region of the pyrin domain as important for SCFA binding. Furthermore, SCFA treatment of macrophages leads to pyroptosis and restricts Salmonella intracellular survival. In addition, SCFA administration to mice induces inflammation and enhances resistance against Salmonella infection. These results suggest the intriguing possibility that eating a diet rich in fiber may protect against Salmonella infection. However, the manuscript is lacking in sufficient context with respect to previous studies involving Salmonella and SFCAs. A number of references important to this work are omitted and not discussed.

Major comments:

1) There is no reference to PMID: 29447698 entitled "Genetic ablation of butyrate utilization attenuates gastrointestinal Salmonella disease". Among other things relevant to this manuscript, this paper showed that butyrate decreased Salmonella colonization of Peyer's patches in gnotobiotic mice.

2) If SCFAs induce ROS by neutrophils (pg 13 line 100), why would Salmonella colonization of the cecum decrease (Fig S9), as ROS induction by Salmonella itself leads to generation of alternative TEAs that allows Salmonella to outcompete microbiota (PMID: 27078066)?

3) What is the rationale behind using STm strain A and needing to compare it to ATCC 14208S?

4) An explanation of how Nlrp3 normally gets activated and interacts with Asc is lacking. What's known and how could SCFAs fit in? Would SCFAs affect nucleation of Asc filaments by Nlpr3, as in Lu et al 2014 Cell (PMID: 24630722).

5) Is it possible that the top band in Fig 1B found in the proprionate and butyrate samples but not the acrylate sample is polymerized Asc?

6) Fig 3A: What is shown in the images? If they are wells with infected monolayers, why are the cells growing in clumps? A scale bar would be useful.

7) Why was procasp-1 and casp-1 precipitated out of the infected monolayer supernatant using acid rather than probed from cell lysate (Fig 3B)?

8) Expression of SPI-1 genes in Salmonella were previously shown to modulate SPI-1 gene expression (PMID: 19433544, PMID: 12453229), but this is not mentioned in the manuscript nor are these papers referenced. Since the SPI-1 T3SS induces inflammasome activation, this is important to address.

9) Fig S3A: Why are Salmonella killed even in the absence of SCFAs during intracellular residence even at time points where no pyroptosis is detected?

10) Are the mice in Fig 4C and Fig 6 pre-treated with antibiotics?

11) In Barthel et al 2003 I&I (PMID: 12704158), Salmonella infection in the absence of antibiotic pre-treatment did not lead to cecal inflammation, which is at odds with Fig 5A.

12) Does SCFA treatment of naïve mice alter tissue architecture?

13) Where are the Salmonella replicating in clodronate-treated mice? Inside other cell types? Extracellularly?

Minor comments:

1) Needs to be made clear that bacteria do not make SCFAs only to regulate immune responses (pg. 11 lines 62-3).

2) Grammatical errors are found in the manuscript. For example, pg 11 line 64.

3) Pg 13 line 107, should be SCFA-bound, not SCFA-found.

4) Fig 4B, "scarify" would be "sacrifice".

Decision Letter 2

Di Jiang, PhD

15 Jun 2020

Dear Dr Kabe,

Thank you for submitting your revised Research Article entitled "Short-chain fatty acids bind to apoptosis-associated speck-like protein to activate inflammasome complex to prevent Salmonella infection" for publication in PLOS Biology. I have now obtained advice from the original reviewers and have discussed their comments with the Academic Editor.

Based on the reviews, we will probably accept this manuscript for publication, assuming that you will modify the manuscript to address the remaining points raised by the reviewers. Please also make sure to address the data and other policy-related requests noted at the end of this email.

We expect to receive your revised manuscript within two weeks. Your revisions should address the specific points made by each reviewer. In addition to the remaining revisions and before we will be able to formally accept your manuscript and consider it "in press", we also need to ensure that your article conforms to our guidelines. A member of our team will be in touch shortly with a set of requests. As we can't proceed until these requirements are met, your swift response will help prevent delays to publication.

*Copyediting*

Upon acceptance of your article, your final files will be copyedited and typeset into the final PDF. While you will have an opportunity to review these files as proofs, PLOS will only permit corrections to spelling or significant scientific errors. Therefore, please take this final revision time to assess and make any remaining major changes to your manuscript.

NOTE: If Supporting Information files are included with your article, note that these are not copyedited and will be published as they are submitted. Please ensure that these files are legible and of high quality (at least 300 dpi) in an easily accessible file format. For this reason, please be aware that any references listed in an SI file will not be indexed. For more information, see our Supporting Information guidelines:

https://journals.plos.org/plosbiology/s/supporting-information

*Published Peer Review History*

Please note that you may have the opportunity to make the peer review history publicly available. The record will include editor decision letters (with reviews) and your responses to reviewer comments. If eligible, we will contact you to opt in or out. Please see here for more details:

https://blogs.plos.org/plos/2019/05/plos-journals-now-open-for-published-peer-review/

*Early Version*

Please note that an uncorrected proof of your manuscript will be published online ahead of the final version, unless you opted out when submitting your manuscript. If, for any reason, you do not want an earlier version of your manuscript published online, uncheck the box. Should you, your institution's press office or the journal office choose to press release your paper, you will automatically be opted out of early publication. We ask that you notify us as soon as possible if you or your institution is planning to press release the article.

*Protocols deposition*

To enhance the reproducibility of your results, we recommend that if applicable you deposit your laboratory protocols in protocols.io, where a protocol can be assigned its own identifier (DOI) such that it can be cited independently in the future. For instructions see: https://journals.plos.org/plosbiology/s/submission-guidelines#loc-materials-and-methods

*Submitting Your Revision*

To submit your revision, please go to https://www.editorialmanager.com/pbiology/ and log in as an Author. Click the link labelled 'Submissions Needing Revision' to find your submission record. Your revised submission must include a cover letter, a Response to Reviewers file that provides a detailed response to the reviewers' comments (if applicable), and a track-changes file indicating any changes that you have made to the manuscript.

Please do not hesitate to contact me should you have any questions.

Sincerely,

Di Jiang, PhD

PLOS Biology

------------------------------------------------------------------------

ETHICS STATEMENT:

-- Please create a separate subsection entitled "Ethics Statement" and place it in the beginning of the Methods section, and please include all relevant information described below.

-- Please include the full name of the IACUC/ethics committee that reviewed and approved the animal care and use protocol/permit/project license. Please also include an approval number.

-- Please include the specific national or international regulations/guidelines to which your animal care and use protocol adhered. Please note that institutional or accreditation organization guidelines (such as AAALAC) do not meet this requirement.

-- Please include information about the form of consent (written/oral) given for research involving human participants. All research involving human participants must have been approved by the authors' Institutional Review Board (IRB) or an equivalent committee, and all clinical investigation must have been conducted according to the principles expressed in the Declaration of Helsinki.

------------------------------------------------------------------------

DATA POLICY:

You may be aware of the PLOS Data Policy, which requires that all data be made available without restriction: http://journals.plos.org/plosbiology/s/data-availability. For more information, please also see this editorial: http://dx.doi.org/10.1371/journal.pbio.1001797

Note that we do not require all raw data. Rather, we ask that all individual quantitative observations that underlie the data summarized in the figures and results of your paper be made available in one of the following forms:

1) Supplementary files (e.g., excel). Please ensure that all data files are uploaded as 'Supporting Information' and are invariably referred to (in the manuscript, figure legends, and the Description field when uploading your files) using the following format verbatim: S1 Data, S2 Data, etc. Multiple panels of a single or even several figures can be included as multiple sheets in one excel file that is saved using exactly the following convention: S1_Data.xlsx (using an underscore).

2) Deposition in a publicly available repository. Please also provide the accession code or a reviewer link so that we may view your data before publication.

Regardless of the method selected, please ensure that you provide the individual numerical values that underlie the summary data displayed in the following figure panels as they are essential for readers to assess your analysis and to reproduce it: Figures 2CD, 3ACDEF, 4ACD, 5DE, 6ABD, 7A-D, S1, S3A-C, S5AB, S6A-D, S7A, S8, S9, S10, S11, S12AB, S15. NOTE: the numerical data provided should include all replicates AND the way in which the plotted mean and errors were derived (it should not present only the mean/average values).

Please also ensure that figure legends in your manuscript include information on where the underlying data can be found, and ensure your supplemental data file/s has a legend.

Please ensure that your Data Statement in the submission system accurately describes where your data can be found.

------------------------------------------------------------------------

BLOT AND GEL REPORTING REQUIREMENTS:

For manuscripts submitted on or after 1st July 2019, we require the original, uncropped and minimally adjusted images supporting all blot and gel results reported in an article's figures or Supporting Information files. We will require these files before a manuscript can be accepted so please prepare and upload them now. Please carefully read our guidelines for how to prepare and upload this data: https://journals.plos.org/plosbiology/s/figures#loc-blot-and-gel-reporting-requirements

------------------------------------------------------------------------

Reviewer remarks:

Reviewer #1: The authors very carefully and thoughtfully revised their manuscript. They added a large amount of additional experimental data to support their hypothesis and address the reviewer's concerns. The additional clarifications helped to make the manuscript more accessible to a larger readership. I have only two minor comments.

Comments:

The authors added a microbiome analysis as requested. Unfortunately, the graphs that were chosen for the manuscript do not actually show that there is no difference in the microbiome composition. The graphs show that there is no difference in alpha diversity, which measures the number and abundance of taxa in a given sample. Alpha diversity can be exactly the same in individuals of two groups while the community composition (which taxa are present) between the groups can be completely different. In order to show that there are no significant differences in community structure between the experimental groups, beta diversity needs to be shown. The microbiota analysis is clearly not the focus of the paper or the expertise of the authors. However, the authors went through the trouble of adding this important piece of data for their mouse experiments. It should therefore be actually significant data that supports their hypothesis. The microbiome data are already available, so adding beta diversity PCA plots should be a minor modification.

The description of the "boost" is misleading. In the results section, the concentrations of the SCFAs in water are not given, only the concentrations for the "boost". This gives the impression that the concentration given by oral gavage is higher than what the mice are drinking throughout the experiment. Through the clarification in M&M I learned that this is not the fact, that the concentration in the boost and in the water are the same. As you explained in the reply to my comment, this was more a "forced drinking" to prevent differences in measurements resulting from that once mouse had recently drank and another an hour ago. You might want to clarify this in the results section.

Reviewer #2: 1) Why is intracellular growth data presented as % CFU in Fig 3 but as CFU/mL in Fig S6B? Also, line 257 should read "non-significant effect" rather than "weak effect".

2) The SPI-1 knockdown mutant induced ASC-dependent IL-1� in BMDMs synergistically with SCFAs, but SCFAs did not potentiate LDH release nor diminish intracellular growth of the SPI-1 mutant. This is in contrast to WT bacterial infection during SCFA treatment, where SCFAs led to significantly less intracellular growth of WT Salmonella and more LDH and IL-1� release. This result is not sufficiently explained.

1) "Butyrate" is misspelled in line 143.

2) Grammatical errors persist.

Decision Letter 3

Gabriel Gasque

24 Aug 2020

Dear Dr Kabe,

On behalf of my colleagues and the Academic Editor, Matthew K. Waldor, I am pleased to inform you that we will be delighted to publish your Research Article in PLOS Biology.

The files will now enter our production system. You will receive a copyedited version of the manuscript, along with your figures for a final review. You will be given two business days to review and approve the copyedit. Then, within a week, you will receive a PDF proof of your typeset article. You will have two days to review the PDF and make any final corrections. If there is a chance that you'll be unavailable during the copy editing/proof review period, please provide us with contact details of one of the other authors whom you nominate to handle these stages on your behalf. This will ensure that any requested corrections reach the production department in time for publication.

Early Version

The version of your manuscript submitted at the copyedit stage will be posted online ahead of the final proof version, unless you have already opted out of the process. The date of the early version will be your article's publication date. The final article will be published to the same URL, and all versions of the paper will be accessible to readers.

PRESS

We frequently collaborate with press offices. If your institution or institutions have a press office, please notify them about your upcoming paper at this point, to enable them to help maximise its impact. If the press office is planning to promote your findings, we would be grateful if they could coordinate with biologypress@plos.org. If you have not yet opted out of the early version process, we ask that you notify us immediately of any press plans so that we may do so on your behalf.

We also ask that you take this opportunity to read our Embargo Policy regarding the discussion, promotion and media coverage of work that is yet to be published by PLOS. As your manuscript is not yet published, it is bound by the conditions of our Embargo Policy. Please be aware that this policy is in place both to ensure that any press coverage of your article is fully substantiated and to provide a direct link between such coverage and the published work. For full details of our Embargo Policy, please visit http://www.plos.org/about/media-inquiries/embargo-policy/.

Thank you again for submitting your manuscript to PLOS Biology and for your support of Open Access publishing. Please do not hesitate to contact us if we can provide any assistance during the production process.

Kind regards,

Pamela Berkman

Publishing Editor,

PLOS Biology

on behalf of

Gabriel Gasque

Senior Editor

PLOS Biology

Associated Data

    This section collects any data citations, data availability statements, or supplementary materials included in this article.

    Supplementary Materials

    S1 Fig. SCFAs enhance IL-1β production induced by NLRP activators.

    IL-1β production in U937 cells stimulated with SCFAs and LPS/nigericin, alum adjuvant, or lethal toxin as measured by ELISA. Data are the mean ± SD of three independent assays. One-way ANOVA analysis, *P < 0.05, **P < 0.01. Data are listed in S1 Data. ANOVA, analysis of variance; IL, interleukin; LPS, lipopolysaccharide; NLRP, nucleotide-binding oligomerization domain-like receptor protein; SCFA, short-chain fatty acid; SD, standard deviation.

    (TIF)

    S2 Fig. Structures of fatty-acid derivatives, including mono-fatty acids, branched carboxylic acids, and di- and tri-carboxylic acids.

    (TIF)

    S3 Fig. Time-course analysis of inflammasome activation by SCFAs in S. Typhimurium–infected BMDMs.

    (A) BMDMs derived from wild-type mice were infected with S. Typhimurium strain A at multiplicity of infection of 5 for 10 minutes and then incubated in DMEM containing 100 μg/mL gentamycin for the indicated time with or without treatment with 10 mM acetate (Ace), propionate (Pro), butyrate (But), or lactate (Lac). Bacterial cell numbers within BMDMs are shown. Data are the mean ± SD of three independent assays. One-way ANOVA analysis, *P < 0.05 versus nontreated BMDMs (ctrl). Data are listed in S1 Data. (B and C) IL-1β production and LDH release in cell-culture media as determined by LDH assay and ELISA, respectively. Data are the mean ± SD of three independent assays. One-way ANOVA analysis, **P < 0.01 versus nontreated BMDMs (ctrl). Data listed in S1 Data. ANOVA, analysis of variance; BMDM, bone marrow–derived macrophage; DMEM, Dulbecco’s modified Eagle’s medium; IL, interleukin; LDH, lactate dehydrogenase; ND, not detected (below the detection limit); S. Typhimurium, S. enterica serovar Typhimurium; SCFA, short-chain fatty acid; SD, standard deviation.

    (TIF)

    S4 Fig. BMDMs derived from ASC- or GPR43-deficient mice.

    (A) PCR analysis of ASC (350-bp PCR product) in genomic DNA isolated from wild-type or ASC–/–mice (left panel). The expression of ASC and F4/80, a macrophage marker, in the bone marrow or in BMDMs derived from wild-type or ASC–/–mice was analyzed by western blotting (right panel). (B) GPR43-deficient mice were generated using CRISPR-Cas9 gene editing. Cas9/gRNA-targeting sites in GPR43. Exons are indicated by closed boxes, and the boxed sequence begins 60 bp from the start codon and contains the targeting sequence in the coding region of exon 3. The gRNA-targeting sequence is underlined, and the PAM sequences are indicated in red. The CRISPR-Cas9 incision site is indicated by an arrow. (C) PCR analysis of GPR43 (390-bp PCR product) in genomic DNA isolated from wild-type or GPR43–/–mice (left panel). GPR43 expression in BMDMs derived from wild-type or GPR43–/–mice was analyzed by western blotting (right panel). ASC, apoptosis-associated speck-like protein; BMDM, bone marrow–derived macrophage; CRISPR-Cas9, clustered regularly interspersed short palindromic repeats–CRISPR-associated protein 9; gRNA, guide RNA; PAM, protospacer adjacent motif; PCR, polymerase chain reaction.

    (TIF)

    S5 Fig. SCFAs do not directly affect S. Typhimurium.

    (A) S. Typhimurium strain A was cultured in LB broth containing 10 mM SCFAs (acetate, propionate, butyrate, or lactate) for the indicated times at 37°C, with agitation. Bacterial growth was monitored by measuring the optical density at 550 nm. Data are listed in S1 Data. (B) Effects of SCFAs on the expression of two flagellin genes of S. Typhimurium strain A. mRNA expression of fliC and fliB was measured by RT-qPCR. Data are the mean ± SD of three independent assays. Data are listed in S1 Data. LB, Luria–Bertani; RT-qPCR, quantitative reverse transcription–polymerase chain reaction; S. Typhimurium, S. enterica serovar Typhimurium; SCFA, short-chain fatty acid; SD, standard deviation.

    (TIF)

    S6 Fig. Effect of SCFAs on inflammasome activation in macrophages infected with an S. Typhimurium SPI-1 knock-down mutant.

    (A) Effects of SCFAs on the expression of SPI-1 genes (sipD and prgH) by S. Typhimurium. The expression of sipD and prgH in S. Typhimurium strain A and the S. Typhimurium SPI-1 knock-down strain were measured by RT-qPCR after SCFA exposure. Data are the mean ± SD of three independent assays. Student's t test, *P < 0.05, **P < 0.01. Data are listed in S1 Data. (B) BMDMs derived from wild-type or ASC−/− mice were infected with SPI-1 knock-down S. Typhimurium at a multiplicity of infection of 5 for 10 minutes and then were incubated in DMEM containing 100 μg/mL gentamycin for 15 hours with or without treatment with acetate (Ace), propionate (Pro), butyrate (But), or lactate (Lac). The percentages of surviving S. Typhimurium SPI-1 knock-down bacteria in SCFA-treated macrophages is shown relative to the survival in untreated macrophages (ctrl). Data are the mean ± SD of three independent assays. Data are listed in S1 Data. (C and D) BMDMs derived from wild-type or ASC−/− mice were infected with SPI-1 knock-down S. Typhimurium at a multiplicity of infection of 5 for 10 minutes and then were incubated in DMEM containing 100 μg/mL gentamycin for 15 hours with or without treatment with 10 mM acetate (Ace), 10 mM propionate (Pro), 10 mM butyrate (But), or 10 mM lactate (Lac). Cell supernatants were collected, and LDH release and IL-1β production were determined by LDH assay and ELISA, respectively. Data are the mean ± SD of three independent assays. One-way ANOVA analysis, *P < 0.05. Data are listed in S1 Data. ANOVA, analysis of variance; BMDM, bone marrow–derived macrophage; DMEM, Dulbecco’s modified Eagle’s medium; LDH, lactate dehydrogenase; ND, not detected (below the detection limit); NS, not significant; RT-qPCR, quantitative reverse transcription–polymerase chain reaction; S. Typhimurium, S. enterica serovar Typhimurium; SCFA, short-chain fatty acid; SD, standard deviation; SPI-1, Salmonella pathogenicity island 1.

    (TIF)

    S7 Fig. Pathogenicity of S. Typhimurium strain A and ATCC14028S strain against mice.

    (A) Survival of SPF wild-type mice infected with S. Typhimurium strain A (108 bacteria) (black circle) and infected with S. Typhimurium ATCC14028S strain (108 bacteria) (blue circle). n = 6 per group. Data listed in S1 Data. (B) HE staining of cecum tissues from SPF wild-type infected with S. Typhimurium strain A or S. Typhimurium ATCC14028S strain. Scale bars = 50 μm. HE, hematoxylin–eosin; S. Typhimurium, S. enterica serovar Typhimurium; SPF, specific pathogen-free.

    (TIF)

    S8 Fig. Gut microbial diversity analysis of wild-type or ASC−/− mice.

    (A) The Shannon diversity index and the Inverse Simpson index were analyzed to compare the microbial diversity between wild-type and ASC−/− mice. The box-and-whisker plots show the full range of variation, the interquartile ranges, and the median values. The data points indicate the diversity indices of each mouse. Data are listed in S1 Data. (B) The two principal coordinates from the PCoA of the weighted UniFrac distances were plotted to the distance matrices for visualization of the microbial diversity. The data points indicate each mouse. Data are listed in S1 Data. ASC, apoptosis-associated speck-like protein; PCoA, principal coordinate analysis.

    (TIF)

    S9 Fig. Effect of antibiotics administration on the concentrations of propionate, butyrate, and lactate in the cecal lumen.

    Mice were given drinking water containing ampicillin (1 g/L), metronidazole (1 g/L), neomycin (1 g/L), and vancomycin (0.5 g/L). After 4 weeks, the mice were humanely killed and cecum samples were collected. Antibiotic-treated mice were given drinking water containing 300 mM propionate, butyrate, or lactate for 1 week, and cecum samples were collected following a boost with propionate, butyrate, and lactate 2 hours prior to killing. n = 5 per group. One-way ANOVA analysis, **P < 0.01. Data are listed in S1 Data. ND, not detected (below the detection limit).

    (TIF)

    S10 Fig. Propionate and butyrate improve the survival of GPR43−/− mice infected with S. Typhimurium.

    GRP43–/–mice treated or not with propionate (n = 7 mice per group) or butyrate (n = 6 mice per group) were infected orally with 108 S. Typhimurium, and survival was monitored. P-values were determined by the log-rank test. Data are listed in S1 Data. S. Typhimurium, S. enterica serovar Typhimurium.

    (TIF)

    S11 Fig. Effects of propionate, butyrate, or lactate on the S. Typhimurium–infected bacterial number in wild-type and ASC−/− mice.

    (A and B) Bacterial cells in the cecum contents, cecum tissues, MLN, liver, and spleen were counted 2 days after infection. Cecum contents and each tissue were homogenized in PBS, and then the homogenates were plated on the Salmonella Shigella selection agar (Difco SS agar) and colony-forming units were counted. Bars indicate the mean (n = 6 per group). One-way ANOVA analysis, *P < 0.05, **P < 0.01. Data are listed in S1 Data. ANOVA, analysis of variance; ASC, apoptosis-associated speck-like protein; MLN, mesenteric lymph node; S. Typhimurium, S. enterica serovar Typhimurium.

    (TIF)

    S12 Fig. The inflammatory infiltrate score and the staining intensity in S. Typhimurium–infected cecal mucosa and submucosa of wild-type or ASC−/− mice.

    (A) The inflammatory infiltrate scores of HE-stained specimens were calculated. Bars indicate the mean (n = 6 per group). One-way ANOVA analysis, *P < 0.05, **P < 0.01. Data are listed in S1 Data. (B) The staining intensities for F4/80 and Gr-1 in the S. Typhimurium–infected cecum tissues of wild-type or ASC−/− mice were quantified using ImageJ analysis software. Bars indicate the mean (n = 6 per group). One-way ANOVA analysis, *P < 0.05. Data are listed in S1 Data. ANOVA, analysis of variance; ASC, apoptosis-associated speck-like protein; HE, hematoxylin–eosin; S. Typhimurium, S. enterica serovar Typhimurium.

    (TIF)

    S13 Fig. The effect of SCFA treatment on SPF mice without S. Typhimurium infection.

    HE staining of cecum tissues from SCFAs-treated SPF wild-type or SPF ASC−/− mice without S. Typhimurium infection. Scale bars = 100 μm. ASC, apoptosis-associated speck-like protein; HE, hematoxylin–eosin; S. Typhimurium, S. enterica serovar Typhimurium; SCFA, short-chain fatty acid; SPF, specific pathogen-free.

    (TIF)

    S14 Fig. Detection of S. Typhimurium in the cecal mucosa and submucosa of mice administered clodronate-encapsulated liposomes.

    Immunostaining of cecum tissues using an anti-F4/80 antibody and an anti–S. Typhimurium LPS antibody. Scale bars = 50 μm. S. Typhimurium, S. enterica serovar Typhimurium.

    (TIF)

    S15 Fig. SCFAs does not activate macrophages in MLN and Peyer's patches through an ASC-dependent mechanism.

    (A) IL-1β production in MLN as determined by ELISA (n = 4 per group). (B) IL-1β production in Peyer’s patches as determined by ELISA (n = 4 per group). Data are listed in S1 Data. ASC, apoptosis-associated speck-like protein; IL, interleukin; MLN, mesenteric lymph node; ND, not detected (below the detection limit).

    (TIF)

    Attachment

    Submitted filename: Point-by-Point response to reviews(PBIOLOGY-D-20-00270R1).docx

    Attachment

    Submitted filename: PbyP response to the latest comments(PBIOLOGY-D-20-00270R3).docx

    Data Availability Statement

    All data can be found in the Supporting information (S1 Data).


    Articles from PLoS Biology are provided here courtesy of PLOS

    RESOURCES